A polypeptide that increases the soluble expression of proteins
By designing a short peptide fusion strategy, the soluble expression level and purification efficiency of proteins in host cells were improved, solving the problem of low protein expression efficiency and achieving efficient protein production.
Patent Information
- Application Number
- CN202610658822.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-11-07
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-17
AI Technical Summary
When proteins are expressed in host cells, they tend to form inactive and toxic aggregates (inclusion bodies), resulting in low expression efficiency, low yield, and poor solubility, which limits the large-scale production and application of proteins.
A short peptide fusion strategy was adopted to design a polypeptide with an amino acid sequence of 6-97 amino acids. By fusing it with the target protein, the solubility and expression level of the protein were improved, the purification process was simplified, and the production cost was reduced.
It significantly improved protein expression levels and solubility, simplified purification steps, reduced production costs, and enhanced the feasibility of industrial protein production.
Smart Images

Figure CN123107948A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of bioengineering and relates to a polypeptide that increases the soluble expression of a protein, and a method for increasing the yield of the strain. Background Technology
[0002] Proteins are essential components of life and are widely used in medicine, biotechnology, and industry. However, protein expression and production face numerous challenges. In genetic engineering, introducing target genes into host cells (such as bacteria, yeast, insect cells, or mammalian cells) for expression is a common method. However, due to the complexity of proteins themselves, post-translational modification requirements, and intracellular environmental factors, problems such as low protein expression efficiency, low yield, and poor solubility severely limit the large-scale production and application of proteins. In the production of functional exogenous (recombinant) proteins in practical quantities, especially when expressed in different recombinant host cells, the proper folding of proteins is of particular concern. This problem can occur in both eukaryotic and prokaryotic host cells. In host cells, misfolding of exogenous proteins during expression often leads to the formation of inactive and toxic aggregates within the cell. Such aggregates are called "inclusion bodies," which cause the protein to lose its activity, making purification and further application difficult. The formation of inclusion bodies is usually due to protein misfolding, exposure of hydrophobic surfaces, and intracellular environmental factors (such as redox state, lack of chaperone proteins, etc.). Therefore, improving the soluble expression of proteins is key to solving the problem of protein production.
[0003] Currently, researchers have developed various strategies to improve protein expression and solubility, including: selecting suitable host cells (for example, Escherichia coli is a commonly used host cell, but the proteins expressed by it tend to form inclusion bodies; eukaryotic expression systems such as yeast, insect cells, and mammalian cells are more suitable for expressing complex proteins due to their more sophisticated post-translational modification mechanisms); optimizing the use of codons in the target gene to match the tRNA abundance of the host cell, thereby improving translation efficiency; and altering the amino acid sequence of the target protein through site-directed mutagenesis or genetic engineering to improve its solubility.
[0004] Previous studies have reported that short peptide fusion strategies can, to some extent, reduce the aggregation of target proteins, improve solubility, and avoid folding interference and degradation caused by the structural complexity of full-length fusion proteins (Dominic E, Deb KC; Current Opinion in Biotechnology 2006, 17:353–358). Furthermore, due to their small molecular weight and relatively simple structure, short peptides typically impose a lower metabolic burden on host cells (such as E. coli and yeast) and cause less interference with host cell growth, thus contributing to the stability of protein expression, facilitating high-density fermentation, and promoting increased yield (Principles of Biochemistry (3rd Edition), 2018).
[0005] Therefore, this application addresses the challenge of soluble protein expression in existing technologies by providing a novel polypeptide. This polypeptide has a small molecular weight and small fragment size, which significantly improves protein expression levels and solubility, making it easier to achieve efficient heterologous expression. Simultaneously, this polypeptide fusion strategy reduces subsequent protein processing steps, such as eliminating enzymatic digestion, thereby simplifying the purification process, reducing production costs, and improving the feasibility of industrial production. Summary of the Invention
[0006] This application provides a polypeptide having an amino acid sequence of 6-97 amino acids, the amino acid sequence of which corresponds to an amino acid sequence of 6-97 consecutive amino acids selected from amino acid residues 256 to 352 in amino acid sequence SEQ ID NO:1. In a preferred embodiment, the amino acid sequence of the polypeptide has 6-29 amino acids, the amino acid sequence of which corresponds to an amino acid sequence of 6-29 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:1. In a preferred embodiment, the amino acid sequence of the polypeptide has 11-29 amino acids, the amino acid sequence of which corresponds to an amino acid sequence of 11-29 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:1. In a preferred embodiment, the amino acid sequence of the polypeptide has 14-29 amino acids, and the amino acid sequence of the polypeptide corresponds to an amino acid sequence consisting of 14-29 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:1. In a preferred embodiment, the amino acid sequence of the polypeptide has 14 amino acids, and the amino acid sequence of the polypeptide corresponds to an amino acid sequence consisting of 14 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:1.
[0007] In some embodiments, the amino acid sequence of the polypeptide has 6-97 amino acids, and the amino acid sequence of the polypeptide comprises or is selected from any of the following: an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 8 consecutive amino acid residues starting from amino acid residue 282 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 8 consecutive amino acid residues starting from amino acid residue 285 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 17 consecutive amino acid residues starting from amino acid residue 288 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 6 consecutive amino acid residues starting from amino acid residue 290 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 14 consecutive amino acid residues starting from amino acid residue 282 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 29 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 6 consecutive amino acid residues starting from amino acid residue 290 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 282 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 282 in amino acid sequence SEQ ID NO:1; or an amino The amino acid sequence consisting of at least 49 consecutive amino acid residues starting from amino acid residue 256 in SEQ ID NO:1, the amino acid sequence consisting of at least 20 consecutive amino acid residues starting from amino acid residue 256 in SEQ ID NO:1, the amino acid sequence consisting of at least 25 consecutive amino acid residues starting from amino acid residue 264 in SEQ ID NO:1, or the amino acid sequence consisting of at least 97 consecutive amino acid residues starting from amino acid residue 256 in SEQ ID NO:1.
[0008] In some embodiments, the amino acid sequence of the polypeptide has 6-29 amino acids. In some embodiments, the amino acid sequence of the polypeptide comprises or is selected from any of the following: an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 8 consecutive amino acid residues starting from amino acid residue 282 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 8 consecutive amino acid residues starting from amino acid residue 285 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 17 consecutive amino acid residues starting from amino acid residue 288 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 6 consecutive amino acid residues starting from amino acid residue 290 in amino acid sequence SEQ ID NO:1; an amino acid sequence consisting of at least 14 consecutive amino acid residues starting from amino acid residue 282 in amino acid sequence SEQ ID NO:1; or an amino acid sequence consisting of at least 29 consecutive amino acid residues starting from amino acid residue 276 in amino acid sequence SEQ ID NO:1.
[0009] In a preferred embodiment, the polypeptide comprises a polypeptide fragment selected from the group consisting of: amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 275 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 352 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 352 of the amino acid sequence shown in SEQ ID NO:1, amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 275 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 352 of the amino acid sequence shown in The amino acids 264 to 288 of the amino acid sequence shown in NO:1, and the polypeptide fragment having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with any of the polypeptide fragments.
[0010] In a preferred embodiment, the polypeptide comprises a polypeptide fragment selected from the group consisting of: amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, and amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, amino acids 286 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, and amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, ...2 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid The amino acids 276 to 304 of the amino acid sequence shown in NO:1, and the polypeptide fragment having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with any of the polypeptide fragments.
[0011] In a preferred embodiment, the polypeptide comprises a polypeptide fragment selected from the group consisting of: amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, and a polypeptide fragment having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with any of the polypeptide fragments.
[0012] In some embodiments, the polypeptide comprises a polypeptide fragment selected from the group consisting of: amino acids 256 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, and a polypeptide fragment having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with any of the polypeptide fragments.
[0013] In a preferred embodiment, the polypeptide comprises a polypeptide fragment selected from the group consisting of: amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, and a polypeptide fragment having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with any of the polypeptide fragments.
[0014] In some embodiments, the amino acid sequence of the polypeptide is selected from SEQ ID NO:2-SEQ ID NO:8, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:62, and SEQ ID NO:64. In some embodiments, the amino acid sequence of the polypeptide is selected from SEQ ID NO:2-SEQ ID NO:8, SEQ ID NO:56, and SEQ ID NO:58. In some embodiments, the amino acid sequence of the polypeptide is selected from SEQ ID NO:2-SEQ ID NO:8. In some embodiments, the amino acid sequence of the polypeptide is selected from SEQ ID NO:58 and SEQ ID NO:2-SEQ ID NO:5. In some embodiments, the amino acid sequence of the polypeptide is selected from SEQ ID NO:5-SEQ ID NO:8.
[0015] SEQ ID NO:1 ERG20 amino acid sequence:
[0016] MASEKEIRRERFLNVFPKLVEELNASLLAYGMPKEACDWYAHSLNYNTPGGKLNRGLSVVDTYAILSNKTVEQLGQEEYEKVAILGWCIELLQAYFLVADDMMDKSITRRGQPCWYKVPEVGEIAINDAFMLEAAIYKLLKSHFRNEKYYIDITELFHEVTFQTELGQLMDLITAP EDKVDLSKFSLKKHSFIVTFKTAYYSFYLPVALAMYVAGITDEKDLKQARDVLIPLGEYFQIQDDYLDCFGTPEQIGKIGTDIQDNKCSWVINKALELASAEQRKTLDENYGKKDSVAEAKCKKIFNDLKIEQLYHEYEESIAKDLKAKISQVDESRGFKADVLTAFLNKVYKRSK
[0017] As an example, the amino acid sequence of the polypeptide may be any of the following:
[0018] SEQ ID NO:2 ERG20(290-295aa) amino acid sequence
[0019] KDSVAE
[0020] SEQ ID NO:3 ERG20(285-292aa) amino acid sequence
[0021] ENYGKKDS
[0022] SEQ ID NO:4 ERG20(282-289aa) amino acid sequence
[0023] TLDENYGK
[0024] SEQ ID NO:5 ERG20(282-295aa) amino acid sequence
[0025] TLDENYGKKDSVAE
[0026] SEQ ID NO:6 ERG20(276-287aa) amino acid sequence
[0027] SAEQRKTLDENY
[0028] SEQ ID NO:7 ERG20(288-304aa) amino acid sequence
[0029] GKKDSVAEAKCKKIFND
[0030] SEQ ID NO:8 ERG20(276-304aa) amino acid sequence
[0031] SAEQRKTLDENYGKKDSVAEAKCKKIFND
[0032] SEQ ID NO:56 ERG20(256-352aa) amino acid sequence
[0033] GTDIQDNKCSWVINKALELASAEQRKTLDENYGKKDSVAEAKCKKIFNDLKIEQLYHEYEESIAKDLKAKISQVDESRGFKADVLTAFLNKVYKRSK
[0034] SEQ ID NO:58 ERG20(256-304aa) amino acid sequence
[0035] GTDIQDNKCSWVINKALELASAEQRKTLDENYGKKDSVAEAKCKKIFND
[0036] SEQ ID NO:62 ERG20(256-275aa) amino acid sequence
[0037] GTDIQDNKCSWVINKALELA
[0038] SEQ ID NO:64 ERG20(264-288aa) amino acid sequence
[0039] CSWVINKALELASAEQRKTLDENYG
[0040] In this invention, the polypeptide can be derived from any host source. In some embodiments, the polypeptide is derived from multiple hosts such as yeast (preferably Saccharomyces cerevisiae), Zymoseptoria tritici, Candida albicans, and Verticillium nonalfalfae. In some embodiments, the polypeptide is derived from yeast, preferably Saccharomyces cerevisiae.
[0041] In this invention, the polypeptide is preferably a polypeptide that increases the soluble expression of a protein. For example, the polypeptide that increases the soluble expression of a protein can enhance the soluble expression of the target protein when it is co-expressed (but not fused) with the target protein in a host cell as (i) a fusion partner of the target protein (e.g., the polypeptide that increases the soluble expression of a protein is fused with the target protein) or (ii) a fusion partner having a target protein binding domain (i.e., the polypeptide that increases the soluble expression of a protein); wherein the target protein binding domain is a polypeptide capable of binding the target protein.
[0042] A second aspect of this application provides a method for increasing the soluble expression of a protein, the method comprising linking a polypeptide as described above to the target protein.
[0043] Meanwhile, a second aspect of this application also provides a method for increasing the soluble expression of a protein, the method comprising co-expressing the polypeptide as described above with a target protein.
[0044] In some embodiments, this application provides a method for increasing the soluble expression of a protein, the method comprising fusing the polypeptide as described above with a target protein for expression.
[0045] A third aspect of the present invention provides a fusion protein comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a polypeptide as described in the first aspect herein.
[0046] In some embodiments, the second polypeptide may be a wild-type protein or a functional mutant thereof. The choice of the second polypeptide depends on the expected biological effect and may be a protein already present in the host cell's natural expression system or a non-natural protein introduced through a recombinant expression system. The functional mutant retains the core biological activity of the wild-type protein while having improved stability, expression levels, or substrate specificity.
[0047] In some embodiments, the second polypeptide is an endogenous protein, that is, a protein naturally encoded by the host cell genome. In other embodiments, the second polypeptide is an exogenous protein, that is, a protein not naturally present in the host cell. For example, the exogenous protein may be derived from a heterologous species or obtained through artificial design.
[0048] In some embodiments, the host cell may be selected from eukaryotic cells or prokaryotic cells.
[0049] In some embodiments, the second polypeptide may be a core functional protein of biometabolism and genetic engineering or a gene regulatory protein. For example, the core functional protein of biometabolism and genetic engineering refers to a protein that plays a key catalytic, regulatory, or structural support role in the metabolism, energy conversion, genetic information transmission, or genetic engineering operations of host cells or organisms. In some embodiments, the second polypeptide may be a core functional protein of biometabolism and genetic engineering or a gene regulatory protein inherent in the host cell or organism itself. Such proteins are naturally encoded by the host cell genome and play a fundamental function in the inherent physiological or metabolic processes of the host cell. By operatively linking the gene encoding such endogenous protein to a strong promoter, inducible promoter, or enhancer element, its overexpression in the host cell can be achieved, thereby upregulating the inherent metabolic pathway activity of the host cell, enhancing genetic stability, or strengthening gene expression regulation capabilities to meet specific engineering application requirements.
[0050] In other embodiments, the second polypeptide may be an exogenously introduced core functional protein or gene regulatory protein for biometabolism and genetic engineering. Such proteins are not naturally encoded in the host cell genome; their encoding genes are introduced into host cells via recombinant expression vectors, site-specific integration mediated by gene editing tools, or other gene transfer techniques. By expressing the exogenous protein, entirely new metabolic branches can be reconstructed or introduced into the host cell, compensating for missing genetic engineering functions in the host cell, or establishing heterologous gene regulatory circuits, thereby endowing the host cell with engineered characteristics exceeding its natural physiological range.
[0051] In some embodiments, the second polypeptide may simultaneously comprise a combination of endogenous and exogenous proteins. For example, basal metabolic flux can be enhanced by overexpressing endogenous metabolic and genetic engineering core functional proteins inherent in the host cell, while exogenous gene regulatory proteins are introduced to construct or control key nodes of specific metabolic pathways, thereby achieving synergistic optimization of metabolic networks and gene expression regulation, improving the synthesis efficiency of target products, the genetic stability of host cells, or the controllability of engineered phenotypes.
[0052] In some embodiments, the core functional proteins of biometabolism and genetic engineering include, but are not limited to, key enzymes, synthases, modifying enzymes, transport proteins, and structural proteins involved in host cell primary metabolism, secondary metabolism, central carbon metabolism, or the synthesis and modification of genetic material. For example, in the terpene compound biosynthesis pathway, the proteins may include terpene synthases (such as gemmaene A synthase, nerolidol synthase, limonene synthase, taxadiene synthase), and precursor supply enzymes (such as geraniylgeraniyl pyrophosphate synthase, farnesyl pyrophosphate synthase, hydroxymethylglutaryl-CoA reductase, key enzymes in the mevalonate pathway, or the methyl erythritol phosphate pathway).
[0053] In some embodiments, the gene regulatory proteins include, but are not limited to, regulatory factors that directly participate in gene transcription, translation, epigenetic modification, genome editing, or intracellular signaling cascade transduction. For example, the gene regulatory proteins may include CRISPR-related proteins (such as Cas9, Cas12a, Cas13a, base editors, leader editors, and mutants lacking nuclease activity).
[0054] In some embodiments, the second polypeptide can be a core functional protein of biometabolism and genetic engineering or a gene regulatory protein, such as: gamma-aluminum A synthase (GAS), terpene synthase (TPS), geraniol-geraniol pyrophosphate synthase (GGPPS), or CRISPR-related protein (Cas protein, such as Cas9, Cas12a, etc.); preferably, the second polypeptide is selected from one or more of gamma-aluminum A synthase (GAS), geraniol-geraniol pyrophosphate synthase, and CRISPR-related protein; more preferably, the second polypeptide is gamma-aluminum A synthase, nerolidol synthase (NES), Cas9, or geraniol-geraniol pyrophosphate synthase (GGPPS); more preferably, the second polypeptide is gamma-aluminum A synthase or nerolidol synthase; most preferably, the second polypeptide is gamma-aluminum A synthase. In some embodiments, the second polypeptide is gamma-aluminum A synthase (GAS).
[0055] In some embodiments, the second polypeptide is geraniylgeraniyl pyrophosphate synthase (GGPPS). In some embodiments, the second polypeptide is Cas9. In some embodiments, the second polypeptide is Cas12a. In some embodiments, the second polypeptide is NES1.
[0056] In a further embodiment, the gemacerene A synthase (GAS) described in this invention refers to an enzyme capable of converting farnesyl pyrophosphate into gemacerene A (Hu Y, Zhou YJ, Bao J, Huang L, Nielsen J, Krivoruchko A. Metabolic engineering of Saccharomyces cerevisiae for production of germacrene A, a precursor of beta-elemene. J Ind Microbiol Biotechnol. 2017 Jul;44(7):1065-1072. doi: 10.1007 / s10295-017-1934-z. Epub 2017 May 25. PMID:28547322.), the gene of which can be cloned from plants or microorganisms known to contain gemacerene A synthase, such as those selected from sunflower (Helianthus annuus L.), chrysanthemum (Tanacetum parthenium), and lettuce (Lactucasativa). Gemmaene synthase was cloned from species such as *Limonium spp.*, *Artemisia carvifolia*, and cyanobacteria. By way of example only, in some specific embodiments, the gammaene synthase is STpGMAs derived from *Dictyophora indicum*; in other specific embodiments, the gammaene synthase is AvGAS derived from the bacterium *Anabaena variabilis*; in other specific embodiments, the gammaene synthase is DeGAS derived from the fungus *Daldinia eschscholtzii*; in other specific embodiments, the gammaene synthase is DlGAS derived from the fungus *Daldinia loculata*; in other specific embodiments, the gammaene synthase is HsGAS derived from the fungus *Hypoxylon sp. EC38*; and in other specific embodiments, the gammaene synthase is LsLTC2 derived from lettuce. In some preferred embodiments, the gammaene synthase is LsLTC2 derived from lettuce.
[0057] In a further embodiment, the geraniol-geraniol pyrophosphate gene of the present invention can be cloned from plants or microorganisms known to contain geraniol-geraniol pyrophosphate synthase, for example, from species selected from *Pseudescherichia vulneris*, *Taxus x media*, *Archaeoglobus fulgidus*, and *Blakeslea trispora*. By way of example only, in some specific embodiments, the geraniol-geraniol pyrophosphate synthase is derived from the geraniol-geraniol pyrophosphate synthase PaCrtE of the bacterium *Pseudescherichia vulneris*. In other specific embodiments, the geraniol-geraniol pyrophosphate synthase is derived from the geraniol-geraniol pyrophosphate synthase AfCrtE of the archaea *Archaeoglobus fulgidus*. In some specific embodiments, the geraniol pyrophosphate synthase is geraniol pyrophosphate synthase BtCrtE derived from the fungus *Blakeslea trispora*. In other specific embodiments, the geraniol pyrophosphate synthase is geraniol pyrophosphate synthase TmCrtE derived from the plant *Taxus X media*. In some preferred embodiments, the geraniol pyrophosphate synthase is geraniol pyrophosphate synthase TmCrtE derived from the plant *Taxus X media*.
[0058] In a further embodiment, the terpene synthase (TPS) of the present invention includes gemmaene A synthase, nerolidol synthase, menthol synthase, limonene synthase, etc.
[0059] In a further embodiment, the CRISPR-related protein (Cas protein) described in this invention refers to a protein in the CRISPR system that has RNA-guided endonuclease activity. Its gene can be cloned from microorganisms known to contain CRISPR-related proteins, such as Streptococcus pyogenes, Staphylococcus aureus, Lachnospiraceae bacterium, Acidaminococcus sp. BV3L6, and Biggiephage. By way of example only, in some specific embodiments, the CRISPR-related protein is SpCas9 derived from Streptococcus pyogenes; in some specific embodiments, the CRISPR-related protein is SaCas9 derived from Staphylococcus aureus; in some specific embodiments, the CRISPR-related protein is LbCas12a derived from Lachnospiraceae bacterium; in some specific embodiments, the CRISPR-related protein is AfCas12a derived from Acidaminococcus sp.; and in some specific embodiments, the CRISPR-related protein is CasΦ (Cas12j) derived from Biggiephage.
[0060] In a further embodiment, the nerolidol synthase (NES) described in this invention is a type of sesquiterpene synthase, referring to a terpene synthase capable of converting farnesyl pyrophosphate into nerolidol. Its gene can be cloned from plants or microorganisms known to contain nerolidol synthase, such as those selected from rose (Rosa chinensis), strawberry (Fragaria ananassa), Tripterygium wilfordii, and kiwifruit (Actinidia chinensis). In some preferred embodiments, the nerolidol synthase is AcNES1 derived from kiwifruit (Actinidia chinensis).
[0061] The second polypeptide described in this invention also includes an amino acid sequence obtained by substitution and / or deletion, or addition / reduction of one or more amino acids based on an enzyme (e.g., a synthase) obtained from the host source described herein, provided that it also possesses the original catalytic activity. For example, for gemmaene A synthase, the original catalytic activity refers to the catalytic synthesis of gemmaene A from farnesyl pyrophosphate (FPP).
[0062] In some preferred embodiments, the gemmaene A synthase has the amino acid sequence shown in SEQ ID NO:16 or an amino acid sequence that is at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to it.
[0063] In some preferred embodiments, the geraniol geraniol pyrophosphate synthase has the amino acid sequence shown in SEQ ID NO:18 or an amino acid sequence that is at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to it.
[0064] In some preferred embodiments, the CRISPR-related protein has an amino acid sequence as shown in SEQ ID NO:50 or SEQ ID NO:52, or an amino acid sequence that is at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to it.
[0065] In some preferred embodiments, the nerolidol synthase has an amino acid sequence as shown in SEQ ID NO:93 or an amino acid sequence that is at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to it.
[0066] In some preferred embodiments of the present invention, based on the amino acid sequences and cDNA sequence information of gemmaene A synthase, geraniylgeraniyl pyrophosphate synthase, CRISPR-related protein and nerolidol synthase, and according to the codon preference of the host cell (engineered bacteria), a codon-optimized coding sequence is synthesized.
[0067] In some specific embodiments, the encoding nucleic acid of the gemmaene A synthase has the nucleic acid sequence shown in SEQ ID NO:17.
[0068] In some specific embodiments, the encoding nucleic acid of the geraniol geraniol pyrophosphate synthase has the nucleic acid sequence shown in SEQ ID NO:19.
[0069] In some specific embodiments, the nucleic acid encoding the CRISPR-related protein has the nucleic acid sequence shown in SEQ ID NO:51 or SEQ ID NO:53.
[0070] In some specific embodiments, the encoding nucleic acid of the nerolidol synthase has the nucleic acid sequence shown in SEQ ID NO:95.
[0071] In a further embodiment, the first polypeptide and the second polypeptide are linked by or without a linker peptide. In some embodiments, the first polypeptide and the second polypeptide are directly linked. In some embodiments, the first polypeptide and the second polypeptide are linked by a linker peptide, which includes, but is not limited to: cleavable linker peptides, non-cleavable linker peptides, peptide linker peptides, flexible linker peptides, rigid linker peptides, helical linker peptides, and non-helical linker peptides. In some embodiments, the linker peptide includes, for example, GGGGS (SEQ ID NO: 109), GSG, YGQ, GGGS, GSGGGGS (SEQ ID NO: 110), GSGEAAAK (SEQ ID NO: 111), GSGEAAAKEAAAK (SEQ ID NO: 112), GSGMGSSSN (SEQ ID NO: 113), PQQKKNS (SEQ ID NO: 114), PGGH, YRSQI (SEQ ID NO: 115), VIPFIS (SEQ ID NO: 116), FLYLKF (SEQ ID NO: 117), WRFSPKLQ (SEQ ID NO: 118), HHVQESQCISTV (SEQ ID NO: 119), PQQKKNSR (SEQ ID NO: 120), AGGGGTGGAAGGGGTGGA (SEQ ID NO: 121), EAAAKEAAAK (SEQ ID NO: 122), PPTPTPTPTP (SEQ ID NO: 123), etc. NO: 123), etc., or one, two, three, four or more repeats of the linker peptide sequence shown above. In some preferred embodiments, the linker peptide of the fusion protein of the present invention is selected from GGGS, PQQKKNSR, AGGGGTGGAAGGGGTGGA, EAAAKEAAAK, PTPTPTPTP. In some more preferred embodiments, the linker peptide of the fusion protein of the present invention is selected from GGGS, PQQKKNSR, AGGGGTGGAAGGGGTGGA. In some more preferred embodiments, the linker peptide of the fusion protein of the present invention is GGGS.
[0072] In some embodiments, the second polypeptide is located at the N-terminus or C-terminus of the first polypeptide. In some embodiments, the second polypeptide is located at the C-terminus of the first polypeptide.
[0073] In some embodiments, the fusion protein of the present invention comprises a first polypeptide and a second polypeptide, and optionally further comprises a linker peptide, wherein the first polypeptide is selected from one or more of SEQ ID NO:2-8, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:62, and SEQ ID NO:64, and the second polypeptide is selected from SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:50, SEQ ID NO:52, and SEQ ID NO:93. In some preferred embodiments, the first polypeptide is selected from one or more of SEQ ID NO:2-8, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:62, and SEQ ID NO:64, and the second polypeptide is selected from SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:50, and SEQ ID NO:93. In some preferred embodiments, the first polypeptide is selected from one or more of SEQ ID NO:2-8, SEQ ID NO:56, and SEQ ID NO:58, and the second polypeptide is selected from one or more of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:50, SEQ ID NO:52, and SEQ ID NO:93. In some preferred embodiments, the first polypeptide is selected from one or more of SEQ ID NO:2-8, SEQ ID NO:56, and SEQ ID NO:58, and the second polypeptide is selected from one or more of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:50, and SEQ ID NO:93. In some preferred embodiments, the first polypeptide is selected from one or more of SEQ ID NO:2-8, and the second polypeptide is selected from one or more of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:50, and SEQ ID NO:93. In some preferred embodiments, the first polypeptide is selected from one or more of SEQ ID NO:2-8, and the second polypeptide is selected from one or more of SEQ ID NO:16 and SEQ ID NO:93.In some embodiments, the fusion protein of the present invention has an amino acid sequence as shown in any one of SEQ ID NO:20-SEQ ID NO:26, SEQ ID NO:78-SEQ ID NO:81, SEQ ID NO:94, SEQ ID NO:105, SEQ ID NO:107, or an amino acid sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some embodiments, the fusion protein of the present invention has an amino acid sequence as shown in any one of SEQ ID NO:20-SEQ ID NO:26, SEQ ID NO:94, SEQ ID NO:105, SEQ ID NO:107 or an amino acid sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the fusion protein has an amino acid sequence as shown in any one of SEQ ID NO:23-SEQ ID NO:26, SEQ ID NO:94, SEQ ID NO:105, SEQ ID NO:107, or an amino acid sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the fusion protein has an amino acid sequence as shown in any one of SEQ ID NO:23-SEQ ID NO:26, SEQ ID NO:94, or an amino acid sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it.In some preferred embodiments, the fusion protein has an amino acid sequence as shown in any one of SEQ ID NO:23-SEQ ID NO:26 or an amino acid sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it.
[0074] In some embodiments, the nucleic acid encoding the fusion protein of the present invention has a nucleotide sequence as shown in any one of SEQ ID NO:27-SEQ ID NO:33, SEQ ID NO:82-SEQ ID NO:85, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some embodiments, the nucleic acid encoding the fusion protein of the present invention has a nucleotide sequence as shown in any one of SEQ ID NO:27-SEQ ID NO:33, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108 or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the nucleic acid encoding the fusion protein has a nucleotide sequence as shown in any one of SEQ ID NO:30-SEQ ID NO:33, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it.In some preferred embodiments, the nucleic acid encoding the fusion protein has a nucleotide sequence as shown in any one of SEQ ID NO:30-SEQ ID NO:33, SEQ ID NO:96, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the nucleic acid encoding the fusion protein has a nucleotide sequence as shown in any one of SEQ ID NO:30-SEQ ID NO:33 or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it.
[0075] In some embodiments, the fusion protein includes a tag. In some embodiments, the tag is selected from one or more of the group consisting of: fluorescent tags, luminescent tags, purification tags, and chromogenic tags. In some specific embodiments, the tag is selected from one or more of the group consisting of: Myc tags, HA tags, VSV-G tags, FLAG tags, V5 tags, and HIS tags (e.g., His*6); preferably, the tag is a Myc tag.
[0076] A fourth aspect of the invention provides isolated nucleic acids comprising a nucleotide sequence encoding a polypeptide as described in the first aspect herein or comprising a nucleotide sequence encoding a fusion protein as described herein.
[0077] In a further embodiment, the nucleic acid encoding the polypeptide as described in the first aspect herein comprises a nucleotide sequence selected from the group consisting of any one of SEQ ID NO:9-SEQ ID NO:15, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:63, SEQ ID NO:65, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with it. In some embodiments, the nucleic acid encoding the polypeptide as described in the first aspect herein comprises a nucleotide sequence selected from the group consisting of: any one of SEQ ID NO:9-SEQ ID NO:15, SEQ ID NO:57, SEQ ID NO:59, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with it. In some embodiments, the nucleic acid encoding the polypeptide as described in the first aspect herein comprises a nucleotide sequence selected from the group consisting of: any one of SEQ ID NO:9-SEQ ID NO:15 or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with it.In some preferred embodiments, the nucleic acid encoding the polypeptide as described in the first aspect herein is a nucleotide sequence as shown in any one of SEQ ID NO:12-SEQ ID NO:15 or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity with it.
[0078] In a further embodiment, the nucleic acid encoding the fusion protein as described herein comprises a nucleotide sequence selected from the group consisting of: any one of SEQ ID NO:27-SEQ ID NO:33, SEQ ID NO:82-SEQ ID NO:85, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity.
[0079] In some embodiments, the nucleic acid encoding the fusion protein of the present invention has a nucleotide sequence as shown in any one of SEQ ID NO:27-SEQ ID NO:33, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108 or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the nucleic acid encoding the fusion protein has a nucleotide sequence as shown in any one of SEQ ID NO:30-SEQ ID NO:33, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the nucleic acid encoding the fusion protein has a nucleotide sequence as shown in any one of SEQ ID NO:30-SEQ ID NO:33, SEQ ID NO:96, or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it. In some preferred embodiments, the nucleic acid encoding the fusion protein has a nucleotide sequence as shown in any one of SEQ ID NO:30-SEQ ID NO:33 or a nucleotide sequence having at least 70% (e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with it.
[0080] A fifth aspect of the invention provides an expression cassette capable of expressing a first polypeptide, a second polypeptide, and / or a fusion protein as described in the first aspect herein, and / or the third aspect herein. In some embodiments, the expression cassette is capable of expressing the first polypeptide and / or the second polypeptide as described in the first aspect herein, or the fusion protein as described in the third aspect herein.
[0081] In some embodiments, the expression cassette includes a nucleic acid encoding a first polypeptide as described in the first aspect herein, a nucleic acid encoding a second polypeptide as described herein, and / or a nucleic acid sequence encoding a fusion protein as described in the third aspect herein.
[0082] In a further embodiment, the expression cassette includes a promoter and a terminator. In a further embodiment, the specific types of the promoter and terminator in the expression cassette are not particularly limited, as long as they can effectively drive and terminate the transcription of the target protein coding sequence in the corresponding host cell. Those skilled in the art can select any suitable promoter and terminator known in the art according to the type of host cell. In some embodiments, the promoter is selected from PPGK1, PTEF2, PTDH3, PICL1, PHXT7, PADH2, PJEN1, PURA3, PGAP, PT7, PGAL1, PGAL10, PPCK1, PHIS3, PTRP1, PFBA1, PTEF1, or PSSA1; preferably, the promoter is selected from PTEF2, PURA3, PGAP, PT7, PGAL1, PGAL10, PHIS3, PTRP1, PFBA1, PTEF1, or PSSA1. In some embodiments, the terminator is selected from TTRP1, TERG12, TERG8, TERG19, THIS3, TERG13, TGAL80, TIDI1, TURA3, TCYC1, TAOX1, TADH2, or TADH1; preferably, the terminator is selected from TTRP1, TERG12, TERG8, TERG19, THIS3, TERG13, TGAL80, TIDI1, TURA3, TCYC1, or TADH1. In some embodiments, the promoter is PSSA1, and the terminator is TADH1. In some embodiments, the promoter is PGAP, and the terminator is TAOX1. In some embodiments, the promoter is PT7, and the terminator is TT7. In some embodiments, the promoter is PSSA1, and the terminator is TADH1.
[0083] In a preferred embodiment, the first polypeptide may be in the same or a different expression cassette as the second polypeptide.
[0084] For example, the expression cassette for the first polypeptide could be Pssa1 - encoding the nucleotide sequence of the first polypeptide - Tadh1, Ptef1 - encoding the nucleotide sequence of the first polypeptide - Tcyc1, etc.
[0085] For example, expression cassettes for the second polypeptide could be Pssa1-encoding the nucleotide sequence of the second polypeptide-Tadh1, Pgap-encoding the nucleotide sequence of the second polypeptide-Taox1, etc.
[0086] In some implementations, the expression cassette for the fusion protein may contain any of the following:
[0087] Promoter - nucleotide sequence encoding the first polypeptide - nucleotide sequence encoding the second polypeptide - terminator;
[0088] Promoter - nucleotide sequence encoding the first polypeptide - nucleotide sequence encoding the linker peptide - nucleotide sequence encoding the second polypeptide - terminator;
[0089] Promoter - nucleotide sequence encoding the second polypeptide - nucleotide sequence encoding the first polypeptide - terminator; or
[0090] Promoter - nucleotide sequence encoding the second polypeptide - nucleotide sequence encoding the linker peptide - nucleotide sequence encoding the first polypeptide - terminator.
[0091] In some implementations, the expression cassette for the fusion protein may contain one or more of the following:
[0092] (a) Pssa1 - Nucleotide sequence encoding the first polypeptide - Nucleotide sequence encoding the second polypeptide - Tadh1
[0093] (b) Pssa1-nucleotide sequence encoding the first polypeptide-GGGS-nucleotide sequence encoding the second polypeptide-Tadh1;
[0094] (c) Pssa1 - nucleotide sequence encoding the second polypeptide - nucleotide sequence encoding the first polypeptide - Tadh1;
[0095] (d) Pssa1-nucleotide sequence encoding the second polypeptide-GGGS-nucleotide sequence encoding the first polypeptide-Tadh1;
[0096] (e) Pgap - nucleotide sequence encoding the first polypeptide - nucleotide sequence encoding the second polypeptide - Taox1;
[0097] (f) Pgap - nucleotide sequence encoding the first polypeptide - GGGS - nucleotide sequence encoding the second polypeptide - Taox;
[0098] (g) Pgap-nucleotide sequence encoding the second polypeptide-nucleotide sequence encoding the second polypeptide-Taoxdh1;
[0099] (h) Pgap-nucleotide sequence encoding the second polypeptide-GGGS-nucleotide sequence encoding the second polypeptide-Taox1;
[0100] (i) Pgap - nucleotide sequence encoding the first polypeptide - nucleotide sequence encoding the second polypeptide - Taox1;
[0101] (j) Pgap-nucleotide sequence encoding the first polypeptide-GGGS-nucleotide sequence encoding the second polypeptide-Taox1;
[0102] (k) Pgap - nucleotide sequence encoding the second polypeptide - nucleotide sequence encoding the first polypeptide - Taox1; or
[0103] (l) Pgap - nucleotide sequence encoding the second polypeptide - GGGS - nucleotide sequence encoding the first polypeptide - Taox1.
[0104] The nucleotide and / or amino acid sequences of the first polypeptide, the second polypeptide, the fusion protein, and the linker peptide are as described herein.
[0105] A sixth aspect of the invention provides a vector comprising a polypeptide as described in the first aspect herein, a fusion protein as described in the third aspect herein, and / or an expression cassette as described in the fourth aspect herein.
[0106] In some embodiments, the vector may include a foreign gene expression cassette for introducing the coding sequence of the polypeptide or fusion protein into a host cell for expression. The foreign gene expression cassette includes a promoter, a target gene encoding the polypeptide or fusion protein as described herein, and a terminator. The foreign gene expression cassette may be integrated into the host cell genome for stable expression in a host cell (e.g., *Saccharomyces cerevisiae*), or it may be expressed as a plasmid outside the host cell genome.
[0107] In some embodiments, the host cell refers to a cell capable of expressing a foreign gene, including prokaryotic cells and eukaryotic cells. The prokaryotic cells include *Escherichia coli*, *Bacillus subtilis*, etc.; the eukaryotic cells include yeast cells, mammalian cells, plant cells, etc. In some embodiments, the host cell is preferably a yeast cell or *Escherichia coli*, and the yeast cells include, but are not limited to, *Saccharomyces cerevisiae*, *Pichia pastoris*, *Candida*, etc.
[0108] In some embodiments, the exogenous gene includes, but is not limited to, genes encoding gemmaene A synthase (GAS), geraniylgeraniyl pyrophosphate synthase (GGPPS), CRISPR-associated protein (Cas protein), and / or nerolidol synthase (NES). The exogenous gene may be a naturally occurring gene sequence or a codon-optimized gene sequence.
[0109] The coding gene in the vector may be a natural polynucleotide sequence encoding a polypeptide as described herein, including a cDNA sequence, a genomic sequence, or an RNA sequence, or a degenerate variant thereof. As used herein, a "degenerate variant" refers to a polynucleotide sequence that encodes the polypeptide but differs from the natural polynucleotide sequence, preferably a codon-optimized DNA sequence. The polynucleotide may be obtained by PCR amplification, recombination, or artificial synthesis.
[0110] In some embodiments, for example, the polypeptide encoded in the vector may be a farnesyl pyrophosphate synthase as described herein, such as ERG20.
[0111] In some embodiments, the polypeptide encoded in the vector may be: (a) a naturally occurring wild-type polypeptide; (b) a polypeptide formed by substitution, deletion or addition of one or more amino acid residues of a wild-type polypeptide, or formed by adding a signal peptide sequence, and having the corresponding activity; (c) a polypeptide containing the polypeptide sequence of (a) or (b); or (d) a polypeptide whose amino acid sequence is ≥85% identical to that of a wild-type polypeptide (preferably ≥90%, more preferably ≥95%) and has the corresponding activity.
[0112] In some embodiments, the vector may be an integrative vector or a free vector. The exogenous gene expression cassette may be integrated into the host cell genome for expression, or it may be expressed as a plasmid outside the genome. The exogenous gene expression cassette includes a promoter, a target gene, and a terminator.
[0113] In some embodiments, the vector is a free vector, which can be any plasmid vector known in the art that can be used to introduce a foreign gene into a host cell for expression. The free vector may include an origin of replication, a selection marker, and the foreign gene expression cassette. In some embodiments, the free vector may be a commercially available vector or any vector with the same function. For example, the free vector may be a yeast expression vector or an *E. coli* expression vector, wherein the yeast expression vector may be a recombinant plasmid constructed based on a backbone such as pRS425, pL2μ, pESC, pPICZαA, etc., for expressing tagged or untagged proteins including, but not limited to, LsLTC2, ERG20 (including full-length or truncated forms), SaCas9, AcNes1, TmCrtE, etc., and their fusion proteins; the *E. coli* expression vector may be a recombinant plasmid constructed based on a backbone such as pET28a.
[0114] In some embodiments, the vector may be an integrative vector, and the method for integrating a foreign gene into the host genome is primarily homologous recombination. Exemplarily, the homologous recombination method includes: amplifying the upstream and downstream sequences of the integration site as an upstream homologous arm and a downstream homologous arm, constructing a target gene expression cassette, typically containing a selection marker gene in the upstream homologous arm; then connecting the above components in the order of the upstream homologous arm, the gene expression cassette, and the downstream homologous arm to form a fragment or recombinant plasmid suitable for homologous recombination; introducing the obtained fragment or recombinant plasmid into a host cell, and screening for positive transformants according to the selection marker to obtain an integrative host (engineered bacteria).
[0115] In some embodiments, the selection markers of the vector include auxotrophic selection markers and resistance selection markers. The auxotrophic selection markers may be LEU2, HIS3, URA3, TRP1, etc. The resistance selection markers may be genimycin G418, bleomycin resistance gene BleoR, hygromycin resistance gene HYG, kanamycin resistance gene (Kan), etc.
[0116] In some embodiments, the vector is a plasmid vector, which can be selected from commonly used expression vectors in the art, such as yeast expression vectors pRS425 series (e.g., pRS425-LEU2), pESC series vectors (e.g., pESC-TRP), yeast expression vectors based on 2μ replicons (e.g., pL2μ series vectors), Escherichia coli expression vectors pET28a series, and Pichia pastoris expression vector pPICZαA, etc.
[0117] In some embodiments, the vector is a plasmid vector selected from pRS425-LEU2, pRS425, pL2μ, pET28a, pESC-TRP, pPICZαA, etc.
[0118] In some embodiments, the vector can be used to introduce homologous recombinant fragments or recombinant plasmids into host cells using methods known in the art. The method for transforming host cells can employ various transformation methods known to those skilled in the art, such as electroconversion, lithium acetate chemical conversion, and calcium chloride chemical conversion.
[0119] In some embodiments, the vector further includes regulatory elements for reducing gene expression levels or enzyme activity. Methods for reducing gene expression levels or enzyme activity include, but are not limited to, replacing promoter elements, gene knockout, site-directed mutagenesis, or RNA interference (RNAi).
[0120] A seventh aspect of the invention provides a recombinant host cell that comprises or expresses a fusion protein as described herein; preferably, the recombinant host cell comprises an expression cassette encoding the fusion protein as described herein.
[0121] In a preferred embodiment, the host cell is yeast or *Escherichia coli*; therefore, the recombinant host cell is also referred to as engineered bacteria. In some embodiments, the host cell is *Pichia pastoris*. In some embodiments, the host cell is *Saccharomyces cerevisiae*. In some embodiments, the host cell is *Escherichia coli*. The yeast or *Escherichia coli* of the present invention can be any yeast or *Escherichia coli* available in the art, such as commercially available *Saccharomyces cerevisiae* CEN.PK2-1D, *Saccharomyces cerevisiae* INVSC1, *Saccharomyces cerevisiae* BY4742, *Saccharomyces cerevisiae* YPH499, *Saccharomyces cerevisiae* W303-1B, *Pichia pastoris* GS115, *Escherichia coli* BL21(DE3), *Escherichia coli* Rosetta, etc.
[0122] In a more preferred embodiment, the host cell may be derived from wild-type yeast or Escherichia coli, or from mutant yeast or Escherichia coli induced by mutagenesis or engineering. In an even more preferred embodiment, the host cell may be derived from wild-type yeast or Escherichia coli capable of providing farnesyl pyrophosphate (FPP), or from mutant yeast or Escherichia coli induced by mutagenesis or engineering.
[0123] For example, host cells may be mutagenized or engineered for screening or biosynthesis purposes. In some embodiments, the host cells may be mutagenized or engineered to confer or enhance specific biological functions to meet the needs of screening marker applications or the biosynthesis of target products. The mutagenesis or engineered modification aims to optimize the host cell's metabolic network, gene expression regulation patterns, or cellular physiological characteristics, including but not limited to increasing the synthesis throughput and conversion rate of target compounds, relieving metabolic bottlenecks or feedback inhibition, reducing byproduct generation, enhancing the cell's tolerance to fermentation environmental stresses (such as product toxicity, osmotic pressure, oxidative stress, or extreme pH), or establishing heterologous biosynthetic pathways to achieve de novo synthesis of non-natural products.
[0124] In some embodiments, the recombinant host cell is an engineered cell that produces isoprene pyrophosphate or terpenoids. In some embodiments, the recombinant host cell contains or expresses a fusion protein of gemmaene synthase as described herein. The host cell described in this invention can be an unmodified or modified host cell. In some embodiments, the modification is the restoration of a specific amino acid synthesis defect (e.g., typically an auxotrophic selection marker), the restoration of which includes, but is not limited to, the following: in situ refilling of a specific nucleotide biosynthesis gene, i.e., repair of inactivation sites; integration of an expression cassette containing an amino acid biosynthesis gene into a non-original gene locus, or expression of the amino acid biosynthesis gene via, for example, a free plasmid, to enhance the host cell's ability to synthesize the corresponding amino acid, thereby using the amino acid biosynthesis gene as an auxotrophic selection marker. In some embodiments, the auxotrophic selection marker can be co-expressed or fused with one or more target genes on the same expression vector, such that, under the selective pressure of the absence of the corresponding amino acid, only the host cell carrying the vector and expressing the amino acid biosynthesis gene can survive and proliferate, thereby simultaneously achieving the selection of transformants and the maintenance of the target gene. Preferably, the selection marker is used for positive or negative selection in multiple rounds of genome editing or continuous transformation. For example, the URA3 marker can be used for negative selection to cyclically knock out endogenous genes, while a new round of positive selection is performed using the complementarity of the same marker. In some embodiments, the modification is an optimization of the mevalonate (MVA) pathway, i.e., by overexpressing the rate-limiting enzyme in the MVA pathway (such as HMG-CoA reductase), eliminating the accumulation of intermediate products in the MVA pathway, balancing the expression levels of various enzymes in the MVA pathway, or by optimizing the codons and promoter strength and increasing the copy number to enhance the metabolic flux of the MVA pathway, thereby increasing the yield of products such as isoprene pyrophosphate or terpenoids.
[0125] In some embodiments, the host cell contains one or more endogenous enzymes, including isopentenyl pyrophosphate isomerase (IDI1), 3-hydroxy-3-methylglutaryl-CoA synthase (ERG13), squalene synthase (ERG9), mevalonate kinase (ERG12), phosphate mevalonate kinase (ERG8), farnesyl pyrophosphate synthase (ERG20), and mevalonate pyrophosphate decarboxylase (ERG19); preferably, the endogenous enzyme includes squalene synthase ERG9. In some embodiments, the host cell contains one or more exogenous enzymes, including acetyl-CoA C-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE, etc.
[0126] In a further embodiment, the host cell comprises any one or more of the following: expressed acetyl-CoA-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE, overexpressed isopentenyl pyrophosphate isomerase IDI1, overexpressed 3-hydroxy-3-methylglutaryl-CoA synthase ERG13, overexpressed mevalonate kinase ERG12, overexpressed phosphate mevalonate kinase ERG8, overexpressed farnesyl pyrophosphate synthase ERG20, and overexpressed mevalonate pyrophosphate decarboxylase ERG19; preferably, the host cell comprises LPP1, responsible for farnesol synthesis, and GAL80, responsible for transcriptional regulation, at inactivated or inhibited activity or expression levels; in a further preferred embodiment, the host cell comprises overexpressed 2 copies of mevalonate kinase ERG12. In some preferred embodiments, the host cell contains an endogenous enzyme with altered expression levels, including squalene synthase ERG9, wherein the activity or expression level of the squalene synthase is weakened (e.g., reduced), and the weakening is achieved by: (a) replacing the promoter of the gene encoding the enzyme; and / or (b) replacing the endogenous enzyme squalene synthase ERG9 with a squalene synthase mutant with reduced expression activity (e.g., ERG9(K325E) or ERG9(R225A)).
[0127] In some embodiments, the yeast host cell further includes one or more of the following characteristics:
[0128] Increase the activity of acetyl-CoA-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE, for example, by increasing its expression level;
[0129] Increased activity of mevalonate kinase ERG12, such as increased expression levels;
[0130] Increased activity of the phosphovalerate kinase ERG8, such as increased expression levels;
[0131] Increased activity of mevalonate pyrophosphate decarboxylase ERG19, for example, increased expression levels;
[0132] Increased activity of farnesyl pyrophosphate synthase ERG20, such as increased expression levels;
[0133] Increased activity of 3-hydroxy-3-methylglutaryl-CoA synthase ERG13, for example, increased expression levels;
[0134] Reduced activity of GAL80, which is responsible for regulating GAL promoter expression, such as reduced expression levels;
[0135] Increased expression activity of isopentenyl pyrophosphate isomerase IDI1, for example, increased levels; or
[0136] Reduced expression levels of LPP1, the gene responsible for farnesol synthesis; or
[0137] Reduced activity of squalene synthase ERG9, for example, reduced expression levels.
[0138] In some embodiments, the yeast host cell further includes one or more of the following characteristics:
[0139] Reduced expression levels of LPP1, the gene responsible for farnesol synthesis;
[0140] Increased activity of acetyl-CoA C-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE;
[0141] Reduced activity of GAL80, which is responsible for regulating GAL promoter expression;
[0142] Increased activity of isopentenyl pyrophosphate isomerase IDI1;
[0143] Increased activity of mevalonate kinase ERG12;
[0144] Increased activity of farnesyl pyrophosphate synthase ERG20;
[0145] Increased activity of mevalonate kinase ERG8;
[0146] Increased activity of mevalonate pyrophosphate decarboxylase ERG19;
[0147] Increased activity of 3-hydroxy-3-methylglutaryl-CoA synthase ERG13; or
[0148] Reduced activity of squalene synthase ERG9, for example, reduced expression levels.
[0149] For example, the increased activity can be achieved by conventional genetic engineering methods, such as by altering its promoter, modifying the enzyme, or increasing its copy number. Alternatively, the increase in activity can be achieved by using the methods described herein, such as co-expression with the polypeptide described in the first aspect (e.g., as a fusion protein, which can be expressed in situ or at a non-original locus), all of which fall within the scope of protection of this application.
[0150] The reduced activity described herein can be achieved through conventional genetic engineering methods, such as by altering promoters, modifying enzymes, knocking out, or reducing copy number.
[0151] In some embodiments, the host cell expresses EfmvaE by introducing / inserting a gene expression cassette encoding acetyl-CoA C-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE.
[0152] In some embodiments, the host cell overexpresses IDI1 by introducing / inserting a gene expression cassette encoding isopentenyl pyrophosphate isomerase IDI1.
[0153] In some embodiments, the host cell overexpresses ERG13 by introducing / inserting a gene expression cassette encoding 3-hydroxy-3-methylglutaryl-CoA synthase ERG13.
[0154] In some embodiments, the host cell overexpresses ERG20 by introducing / inserting a gene expression cassette encoding farnesyl pyrophosphate synthase ERG20.
[0155] In some embodiments, the host cell overexpresses ERG12 by introducing / inserting a gene expression cassette encoding mevalonate kinase ERG12.
[0156] In some embodiments, the host cell overexpresses ERG8 by introducing / inserting a gene expression cassette encoding mevalonate phosphokinase ERG8.
[0157] In some embodiments, the host cell overexpresses ERG19 by introducing / inserting a gene expression cassette encoding mevalonate pyrophosphate decarboxylase ERG19.
[0158] In some embodiments, GAL80 and / or LPP1 are inactivated or inhibited by disrupting, substituting, deleting, or knocking out GAL80 and / or LPP1 in host cells (e.g., yeast cells). In some preferred embodiments, GAL80 and / or LPP1 are inactivated by knocking out GAL80 and / or LPP1 in yeast. In some preferred embodiments, the host cell is used by inserting a gene expression cassette encoding a squalene synthase ERG9 mutant and knocking out endogenous squalene synthase, wherein the ERG9 mutant is ERG9 (K325E) or ERG9 (R225A).
[0159] In some embodiments, the host cell includes one or more expression cassettes, each including a promoter, a coding sequence, and a terminator. The promoter and terminator may be selected from functional promoters and terminators suitable for the host cell, respectively. The host cell may be a eukaryotic or prokaryotic cell, such as a yeast cell or an Escherichia coli cell.
[0160] In some embodiments, the expression cassette is used to express metabolic pathway-related enzymes, regulatory proteins, and target proteins. In some embodiments, the metabolic pathway-related enzymes include, but are not limited to, ERG12, ERG8, ERG19, ERG20, IDI1, ERG13, EfmvaE, LPP1, etc. In some embodiments, the regulatory proteins include, but are not limited to, ERG9 or its mutants (e.g., ERG9(R225A) or ERG9(K325E)), GAL80, etc. In some embodiments, the target protein includes the first polypeptide, the second polypeptide, or a fusion protein thereof as described herein.
[0161] For example, in some embodiments, the host cell (e.g., yeast cell) contains or expresses a fusion protein of the gemmaene synthase as described herein, and optionally has enhanced activity of farnesyl pyrophosphate synthase ERG20.
[0162] In some embodiments, the expression cassette may be a yeast expression cassette, with its promoter selected from PSSA1, PTEF1, PTEF2, PFBA1, PERG9, PGAL1, PGAL10, PTRP1, PHIS3, or PURA3, and its terminator selected from TADH1, TCYC1, TERG8, TERG9, TERG12, TERG19, TIDI1, TGAL80, TTRP1, THIS3, or TURA3. In some embodiments, the promoter is PSSA1 and the terminator is TADH1. In some embodiments, the promoter is PGAP and the terminator is TAOX1.
[0163] In other embodiments, the expression cassette may be an Escherichia coli expression cassette, with a T7 promoter and a terminator suitable for the T7 transcription system.
[0164] In a preferred embodiment, multiple expression cassettes can be cascaded together to form a multi-gene expression module for the simultaneous expression of multiple metabolic pathway enzymes and / or target proteins in the same host cell.
[0165] In some embodiments, the expression box includes a promoter and a terminator, wherein the promoter includes, but is not limited to, PTEF1, PTEF2, PTRP1, PERG12, PFBA1, PHIS3, PGAL1, PGAL10, PURA3, PSSA1, PERG9, PGAP, or PPGK1. In some embodiments, the terminator includes, but is not limited to, TADH2, TADH1, TTRP1, TERG12, TERG8, TERG19, THIS3, TERG13, TGAL80, TURA3, TCYC1, TIDI1, or TERG9.
[0166] In some embodiments, the expression cassettes are Ptrp1-TRP1-Ttrp1, Ptef1-ERG12-Terg12, Pfba1-ERG8-Terg8, Ptef2-ERG19-Terg19, Phis3-HIS3-This3, Ptef1-ERG12-Terg12, Terg13(RC)-ERG13(RC)-Pgal1(RC), Pgal10-EfmvaE-Tgal80, Pura3-URA3- Tura3, Ptef1-ERG20-Tadh1, Ptef2-IDI1-Tidi1, Pura3-URA3-Tura3, Perg9-ERG9(R225A)-Terg9, Perg9-ERG9(K325E)-Terg9, Ptef-KanMX-Tadh2, Pgap-LsLTC2-Taox1, Pgap-truncated ERG20-optional linker peptide coding sequence-LsLTC2-Taox1-BleoR, etc.
[0167] For example, the expression cassettes are Ptrp1-TRP1-Ttrp1-Ptef1-ERG12-Terg12-Pfba1-ERG8-Terg8-Ptef2-ERG19-Terg19 (SEQ ID NO:45), Phis3-HIS3-This3-Ptef1-ERG12-Terg12-Terg13-ERG13-Pgal1-Pgal10-EfmvaE-Tgal80 (SEQ ID NO:46), Pura3-URA3-Tura3-Ptef1-ERG20-Tadh1-Ptef2-IDI1-Tidi1 (SEQ ID NO:47), trp1-289::TRP1 (SEQ ID NO: 48), Pura3-URA3-Tura3-Phis3-HIS3-This3 (SEQ ID NO:48). NO: 49), Ptrp1-TRP1-Ttrp1-Perg9-ERG9(R225A)-Terg9 (SEQ ID NO: 90) or Ptrp1-TRP1-Ttrp1-Perg9-ERG9(K325E)-Terg9 (SEQ ID NO: 91), Δerg9-Ptef-KanMX-Tadh2 (SEQ ID NO: 92), Pgap-LsLTC2-Taox1-BleoR (SEQ ID NO: 66), Pgap-tERG20-LsLTC2-Taox1-BleoR (SEQ ID NO: 77), etc.
[0168] In some embodiments, the expression cassette is Ptrp1-TRP1-Ttrp1-Ptef1-ERG12-Terg12-Pfba1-ERG8-Terg8-Ptef2-ERG19-Terg19, whose structure consists of the nucleotide sequence shown in SEQ ID NO:45, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:45, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:45; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:45.
[0169] In some embodiments, the expression cassette is Phis3-HIS3-This3-Ptef1-ERG12-Terg12-Terg13-ERG13-Pgal1-Pgal10-EfmvaE-Tgal80, whose structure consists of the nucleotide sequence shown in SEQ ID NO:46, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:46, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:46; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:46.
[0170] In some embodiments, the expression cassette is Pura3-URA3-Tura3-Ptef1-ERG20-Tadh1-Ptef2-IDI1-Tidi1, whose structure consists of the nucleotide sequence shown in SEQ ID NO:47, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:47, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:47; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:47.
[0171] In some embodiments, the expression cassette is Pura3-URA3-Tura3-Phis3-HIS3-This3, whose structure consists of the nucleotide sequence shown in SEQ ID NO:49, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:49, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:49; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:49. In some embodiments, the expression cassette is Ptrp1-TRP1-Ttrp1-Perg9-ERG9(R225A)-Terg9, whose structure consists of the nucleotide sequence shown in SEQ ID NO:90, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:90, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:90; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:90.
[0172] In some embodiments, the expression cassette is Ptrp1-TRP1-Ttrp1-Perg9-ERG9(K325E)-Terg9, whose structure consists of the nucleotide sequence shown in SEQ ID NO:91, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:91, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:91; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:91.
[0173] In some embodiments, the expression cassette is Δerg9-Ptef-KanMX-Tadh2, whose structure comprises the nucleotide sequence shown in SEQ ID NO:92, or a nucleotide sequence having at least 90% sequence identity with the nucleotide sequence shown in SEQ ID NO:92, for example, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In a preferred embodiment, the nucleotide sequence of the expression cassette has at least 95% sequence identity with the sequence shown in SEQ ID NO:92; in a more preferred embodiment, the nucleotide sequence of the expression cassette has at least 99% sequence identity with the sequence shown in SEQ ID NO:92.
[0174] In a further embodiment, the host cell is prepared by containing or expressing a fusion protein of the gemmaene synthase as described herein in *Saccharomyces cerevisiae* (e.g., *Saccharomyces cerevisiae* CEN.PK2-1D), and optionally having enhanced activity of farnesyl pyrophosphate synthase ERG20. In a further embodiment, the host cell is prepared by inserting expression cassettes of ERG12, ERG8, ERG19, ERG12, ERG13, EfmvaE, ERG20, and IDI1 at one or more sites in the genome of *Saccharomyces cerevisiae* (e.g., *Saccharomyces cerevisiae* CEN.PK2-1D) using auxotrophic selection markers (including but not limited to LEU, TRP1, HIS, URA, etc.), while simultaneously knocking out GAL80 and LPP1. In some embodiments, the expression cassette may be inserted at the desired gene knockout site to achieve both insertion and knockout simultaneously. In a further embodiment, the host cell is prepared by inserting ERG12, ERG8, and ERG19 into neutral sites such as XI-3, 1622b, 416d, or XII-1 in *Saccharomyces cerevisiae* (e.g., *CEN.PK2-1D*), using auxotrophic selection markers (including but not limited to LEU, TRP1, HIS, URA, etc.), inserting ERG12, ERG13, and EfmvaE expression cassettes into the GAL80 site while knocking out GAL80; and inserting ERG20 and IDI1 expression cassettes into the LPP1 site while knocking out LPP1.
[0175] In a further embodiment, the host cell is selected by inserting Ptrp1-TRP1-Ttrp1-Ptef1-ERG12-Terg12-Pfba1-ERG8-Terg8-Ptef2-ERG19-Terg19 (SEQ ID NO:45) into the XI-3 site of CEN.PK2-1D Saccharomyces cerevisiae, and then screening using the TRP1 selection marker; knocking out GAL80, and inserting Phis3-HIS3-This3-Ptef1-ERG12-Terg12-Terg13-ERG13-Pgal1-Pgal10-EfmvaE-Tgal80 (SEQ ID NO:46) into the GAL80 site, and then screening using the HIS selection marker; after LPP1 knockout, inserting Pura3-URA3-Tura3-Ptef1-ERG20-Tadh1-Ptef2-IDI1-Tidi1 (SEQ ID NO:46) into the LPP1 site. NO:47), filter using URA3 filter markers.
[0176] In some embodiments, the host cell is selected by backfilling the TRP1 gene at the trp1-289 site in CEN.PK2-1D Saccharomyces cerevisiae; knocking out LPP1; inserting Pura3-URA3-Tura3-Phis3-HIS3-This3 (SEQ ID NO:49) at the LPP1 site; and using URA3 and HIS3 selection markers.
[0177] Furthermore, in some embodiments, the host cell inserts Ptrp1-TRP1-Ttrp1-Perg9-ERG9(R225A)-Terg9 (SEQ ID NO:90) or Ptrp1-TRP1-Ttrp1-Perg9-ERG9(K325E)-Terg9 (SEQ ID NO:91) at site 1622b, and knocks out endogenous ERG9 using the kanMX selection marker.
[0178] In a preferred embodiment, the present invention provides a host cell containing or expressing the above-mentioned fusion protein. The host cell is selected from yeast and *Escherichia coli*, preferably from *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Escherichia coli*, with *Saccharomyces cerevisiae* being the most preferred. In a specific embodiment, the host cell is an unmodified or modified host cell. Preferably, the modification is an MVA pathway optimization, which is achieved by introducing the gene encoding the heterobifunctional enzyme acetyl-CoA C-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE into the host cell, overexpressing isopentenyl pyrophosphate isomerase IDI1, overexpressing 3-hydroxy-3-methylglutaryl-CoA synthase ERG13, overexpressing mevalonate kinase ERG12, overexpressing phosphate mevalonate kinase ERG8, overexpressing farnesyl pyrophosphate synthase ERG20, and overexpressing mevalonate pyrophosphate decarboxylase ERG19. In some preferred embodiments, the host cell contains inactivated or inhibited LPP1, responsible for farnesol synthesis, and GAL80, responsible for transcriptional regulation. In some preferred embodiments, the host cell contains overexpressed 2 copies of mevalonate kinase ERG12. Further, in some preferred embodiments, the host cell is formed by replacing endogenous squalene synthase with a squalene synthase mutant.
[0179] In some embodiments, the available yeast gene selection markers can be any selection marker known to those skilled in the art, as long as the selection markers used when introducing different fragments or plasmids into the same yeast strain are different from each other. Common selection markers include auxotrophic selection markers and resistance selection markers. Among them, auxotrophic selection markers can be selected from LEU2, HIS3, URA3, or TRP1. Resistance selection markers can be genimycin G418, bleomycin resistance gene BleoR, or hygromycin resistance gene HYG.
[0180] In some implementations, the available E. coli selection markers can be any selection marker known to those skilled in the art, as long as the selection markers used when introducing different fragments or plasmids into the same E. coli are different from each other. Common selection markers include resistance selection markers, such as the ampicillin resistance gene Amp, the kanamycin resistance gene Kan, and the chloramphenicol resistance gene.
[0181] The eighth aspect of this invention provides the use of the polypeptide or fusion protein comprising the first aspect herein, or a host cell. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble proteins. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble gemathene A synthase. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble geraniol-geraniol pyrophosphate synthase. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble LsLTC2. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble TmCrtE. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble CRISPR-related proteins. In some embodiments, the polypeptide as described in the first aspect of this invention has the use of promoting the expression of soluble AcNES1 protein.
[0182] In a further embodiment, the fusion protein comprising the polypeptide described in the first aspect of the present invention has the use in producing terpenoids (such as gemathene A, elemene), geraniol diphosphate, carotenoids, and nerolidol. In a further embodiment, the fusion protein comprising the polypeptide described in the first aspect of the present invention has the use in producing terpenoids (such as gemathene A, elemene), geraniol diphosphate, and nerolidol, depending on the fused protein. In some preferred embodiments, the fusion protein comprising the polypeptide described in the first aspect of the present invention comprises gemathene A synthase and has the use in producing gemathene A. In some preferred embodiments, the fusion protein comprising the polypeptide described in the first aspect of the present invention comprises gemathene A synthase and has the use in producing elemene. In some preferred embodiments, the fusion protein comprising the polypeptide described in the first aspect of the present invention comprises geraniol-geraniol pyrophosphate synthase and has the use in producing geraniol diphosphate. In some preferred embodiments, the fusion protein comprising the polypeptide described in the first aspect of the present invention also has the use in producing carotenoids, depending on the fused protein. In some preferred embodiments, the fusion protein comprising the polypeptide described in the first aspect of the invention comprises nerolidol synthase and is used for the production of nerolidol.
[0183] The recombinant host cells (or engineered bacteria) described in this invention can have a variety of uses, such as for the production of terpenoid compounds, including but not limited to gemmaene A, elemene, valenene, nerolidol, etc.; for the production of geraniol diphosphate; and for the production of CRISPR-related proteins.
[0184] Furthermore, the recombinant host cells (or engineered bacteria) described in this invention have a higher yield of terpenoids compared to wild-type host cells, such as higher production of gemmaene A and / or higher production of nerolidol.
[0185] The tenth aspect of this invention provides a method for producing terpenoid compounds, the method comprising culturing and fermenting recombinant host cells as described herein to obtain the terpenoid compounds, wherein the terpenoid compounds include, but are not limited to, gemmaene A, elemene, valenene, nerolidol, etc. The recombinant host cells contain or express corresponding terpenoid synthases, particularly the fusion protein described in this application.
[0186] The eleventh aspect of this invention provides a method for producing gemathene A or nerolidol, the method comprising culturing and fermenting a recombinant host cell as described herein. The recombinant host cell contains or expresses an enzyme that synthesizes the corresponding gemathene A or nerolidol, the synthase preferably being in the form of a fusion protein comprising the polypeptide of the first aspect herein.
[0187] The eleventh aspect of this invention provides a method for producing β-elemene, comprising the following steps:
[0188] 1) Fermenting the recombinant host cell or engineered bacteria described herein to obtain a fermentation broth, wherein the recombinant host cell or engineered bacteria contains or expresses a corresponding gemathene synthase, wherein the synthase is preferably in the form of a fusion protein containing the polypeptide of the first aspect herein;
[0189] 2) Extract the fermentation broth with an organic solvent and collect the organic phase;
[0190] 3) The organic phase is heated to obtain β-elemene.
[0191] The fermentation described in step 1) includes yeast fermentation and / or Escherichia coli fermentation. Yeast fermentation and / or Escherichia coli fermentation can be carried out using methods known in the art.
[0192] In some embodiments, the fermentation includes biphasic fermentation or monophasic fermentation.
[0193] In some embodiments, the fermentation temperature is 16-40°C. In some embodiments, the fermentation temperature is 16-37°C. In some embodiments, the fermentation temperature is 37°C. In some embodiments, the fermentation temperature is 30°C. In some embodiments, the fermentation temperature can be 16-30°C. In some embodiments, the fermentation temperature can be 20-30°C. In some embodiments, the fermentation temperature is 25°C. In some embodiments, the fermentation temperature is 30°C.
[0194] In some embodiments, the fermentation speed is 100-500 rpm. In some embodiments, the fermentation speed is 250 rpm.
[0195] In some embodiments, the fermentation time is in the range of 40-144 hours. In some embodiments, the fermentation time is in the range of 40-120 hours. In some embodiments, the fermentation time is in the range of 40-72 hours.
[0196] In some embodiments, the fermentation is a single-phase yeast fermentation. The single-phase yeast fermentation includes inoculating a single clone of the host cell into a fermentation medium, fermenting at 30°C, rotating at 250 rpm, and fermenting for 40-72 hours. Before inoculation into the fermentation medium, the host cell may undergo expansion culture, including single-stage or multi-stage expansion culture. In some specific embodiments, the single-phase yeast fermentation includes inoculating a single clone of the host cell into a fermentation medium, fermenting at 30°C, rotating at 250 rpm, and fermenting for 72 hours; or, the single-phase yeast fermentation includes inoculating a single clone of the host cell into a fermentation medium, fermenting at 30°C, rotating at 250 rpm, and fermenting for 40 hours. Before inoculation into the fermentation medium, the host cell may undergo expansion culture, including single-stage or multi-stage expansion culture.
[0197] In some embodiments, the fermentation is a yeast biphasic fermentation. The yeast biphasic fermentation includes: (1) inoculating the host cell monoclonal onto an amplification medium, fermenting at 30°C and 250 rpm, and culturing with shaking for 120-168 h; (2) transferring the cultured bacterial solution at 5 vol%-10 vol% transfer volume to Erlenmeyer flasks containing fermentation medium and n-dodecane, fermenting at 30°C and 250 rpm, and culturing for 120-168 h. In some embodiments, the fermentation is an Escherichia coli biphasic fermentation, including: (1) inoculating the host cell monoclonal onto an amplification medium, fermenting at 30°C and 250 rpm, and culturing overnight; (2) transferring the cultured bacterial solution at 5 vol%-10 vol% transfer volume to Erlenmeyer flasks containing fermentation medium and n-dodecane, fermenting at 30°C and 250 rpm, and culturing for 72-120 h. In biphasic fermentation, specifically, the host cells may undergo primary or multi-stage expansion culture before being inoculated into the fermentation medium.
[0198] In some embodiments, the fermentation process may produce terpenoid compounds, such as gemmaene A and nerolidol.
[0199] In some embodiments, the gemmaene A is extracted by extraction or chromatography. In some embodiments, the organic solvent used for extraction includes, but is not limited to, n-dodecane, isopropyl myristate, n-hexane, and n-heptane. In some embodiments, the organic solvent used for extraction is n-dodecane.
[0200] In some embodiments, the gemmaene A can be converted into β-elemene by heating.
[0201] Finally, the present invention provides the use of squalene synthase ERG9 mutants in the production and / or improvement of elemol yield, wherein the squalene synthase ERG9 mutants are ERG9(K325E) and / or ERG9(R225A).
[0202] The beneficial effects of this invention are:
[0203] The polypeptide fragments described in this invention are small in size and molecular weight, which can effectively enhance the soluble expression of proteins and facilitate efficient heterologous expression. Simultaneously, the polypeptide fusion eliminates the need for enzymatic digestion, reducing purification reagents and time, thereby simplifying the purification process, lowering production costs, and ultimately achieving efficient product production and industrialization.
[0204] definition
[0205] Unless otherwise stated, the following terms as used in this disclosure have the following meanings. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.
[0206] The term "wild type" refers to either a naturally occurring polynucleotide sequence or a portion thereof that encodes a protein, or a protein sequence or a portion thereof, as is commonly found in the body.
[0207] The term "nucleic acid" is well-known in the art. As used herein, "nucleic acid" generally refers to a molecule (i.e., a chain) containing a nucleobase, such as DNA, RNA, or derivatives or analogs thereof. Nucleobases include, for example, naturally occurring purine or pyrimidine bases found in DNA (e.g., adenine "A", guanine "G", thymine "T", or cytosine "C") or naturally occurring purine or pyrimidine bases found in RNA (e.g., A, G, uracil "U", or C). The term "nucleic acid" encompasses the terms "oligonucleotide" and "polynucleotide".
[0208] In this document, unless otherwise specified, the position numbering and orientation of all amino acid sequences in this application are based on the direction from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus), where the first position corresponds to the N-terminal starting amino acid, and subsequent positions increase sequentially towards the C-terminus; the position numbering and orientation of all nucleotide sequences are based on the direction from the 5' end to the 3' end, where the first position corresponds to the 5' end starting nucleotide, and subsequent positions increase sequentially towards the 3' end.
[0209] In this document, the term "exogenous" refers to a substance present in a cell that is not of its natural origin. When used herein, the term "exogenous" refers to nucleic acids (e.g., nucleic acids encoding gimabenene synthase) or proteins (e.g., gimabenene synthase polypeptides) introduced into a biological system (such as a cell or organism) through a process involving artificiality, which are not normally present in the biological system or are present in a low amount in the biological system. If the substance is introduced into a cell or the ancestral cell of said cell (which genetically inherits the substance), then said substance (e.g., nucleic acids encoding gimabenene synthase transcription factors; or proteins, such as gimabenene synthase polypeptides) would be considered exogenous. Conversely, the term "endogenous" refers to a substance inherent in the biological system or cell (e.g., differentiated cells).
[0210] Furthermore, when a nucleic acid sequence is identical or substantially identical to a naturally occurring endogenous gene sequence in the host cell genome (e.g., the endogenous gene sequence encoding mevalonate kinase ERG12), but this nucleic acid is introduced into the cell or the cell's progenitor cell through an artificial process (such as recombinant expression vectors, transposon systems, gene editing-mediated heterologous site integration, or other gene transfer techniques) and expressed at a site outside the original genomic locus of the endogenous gene, then this nucleic acid is still considered a foreign nucleic acid, and the integration site or the carrier it carries is considered a foreign expression unit. However, a protein encoded by the aforementioned ectopically introduced endogenous gene sequence (e.g., mevalonate kinase ERG12 encoded by the ectopically introduced endogenous mevalonate kinase ERG12 gene), if its amino acid sequence is identical or substantially identical to the naturally encoded endogenous protein sequence of the host cell, then this protein is still considered, in terms of functional classification, an overexpressed form or functional equivalent of the endogenous protein, and is not classified as a foreign protein due to the ectopic introduction of the encoding gene or the presence of a foreign expression unit.
[0211] In this document, "fusion coupler of target protein" refers to a single polypeptide chain expressed and translated by directly linking the nucleotide sequence encoding the polypeptide of the present invention with the nucleotide sequence encoding the target protein within the same reading frame. The fusion coupler can be linked via an optional linker peptide or directly.
[0212] In this document, the term "fusion coupler having a target protein binding domain" refers to a recombinant protein comprising: (a) the polypeptide described in this invention; and (b) a target protein binding domain capable of specifically and non-covalently binding to a target protein (e.g., antigen-antibody binding, receptor-ligand binding, or polypeptide-polypeptide interaction), thereby enabling the fusion coupler and the target protein to form a coexisting protein complex after expression.
[0213] In this paper, "increased protein soluble expression" means that in host cells, when a target protein is co-expressed with its fusion partner, the soluble expression level of the target protein is increased compared to when it is expressed alone.
[0214] In this document, the terms "identity," "sameness," "sequence identity," or "identity percentage" for amino acid sequences are used interchangeably and refer to the degree of residue matching between two polynucleotide or polypeptide sequences at optimal alignment. The percentage is calculated by comparing the sequence to be tested with the reference sequence of this invention and determining the proportion of identical residues across the full length of the reference sequence. Alignment procedures and algorithms used to determine sequence identity include BLASTP, BLASTN, ALIGN, etc., using default parameters. When alignment discrepancies arise between the algorithms or procedures, the result calculated using NCBI BLAST 2.0 software with default parameters is taken as the final criterion.
[0215] A promoter is a region of nucleic acid sequence that controls the initiation and rate of transcription. It may contain elements that allow regulatory proteins and molecules (such as RNA polymerases and other transcription factors) to bind to it to initiate specific transcription of the nucleic acid sequence.
[0216] A terminator is a sequence-based element that defines the end of a transcriptional unit (such as a gene) and initiates the release of newly synthesized RNA from the transcriptional mechanism. Terminators are located downstream of the gene to be transcribed and typically appear directly after any 3' regulatory element, such as polyadenylation or poly(A) signaling.
[0217] As used in this article, the term "engineered bacteria" refers to host cells that have been genetically engineered to express exogenous genes and produce target products, preferably microorganisms such as Saccharomyces cerevisiae and Escherichia coli.
[0218] Unless the context clearly indicates otherwise, singular terms in this document encompass plural referents, and vice versa. Similarly, nouns without a defined quantity also include plural referents. Unless otherwise stated, the words “a” or “an” in this document mean “at least one” or “at least one”. Unless the context clearly indicates otherwise, the word “or” in this document is intended to include “and”.
[0219] In this document, unless otherwise stated, the terms “comprise, comprises, and comprising” or their equivalents (e.g., contain, containing, include, including) are open-ended expressions and should be understood as “including but not limited to”, meaning that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be covered. Attached Figure Description
[0220] Figure 1 The diagram shows a Western blot analysis of the soluble expression products of the peptide and LsLTC2 protein according to the present invention in Saccharomyces cerevisiae. The loading order from left to right is as follows: Lane 1: protein standard band; Lane 2: CEN2185; Lane 3: CEN2186; Lane 4: CEN2187; Lane 5: CEN2188; Lane 6: CEN2189; Lane 7: CEN2181; Lane 8: CEN2183.
[0221] Figure 2 The diagram shows a Western blot analysis of the soluble expression products of the peptide and TmCrtE protein according to the present invention. The loading order from left to right is as follows: Lane 1: Protein standard band; Lane 2: 24h_CEN3213 sample 1; Lane 3: 24h_CEN3213 sample 2; Lane 4: 28h_CEN3210 sample 1; Lane 5: 28h_CEN3210 sample 2; Lane 6: 28h_CEN3213 sample 1; Lane 7: 28h_CEN3213 sample 2; Lane 8: 32h_CEN3210 sample 1; Lane 9: 32h_CEN3210 sample 2; Lane 10: 32h_CEN3213 sample 1; Lane 11: 32h_CEN3213 sample 2.
[0222] Figure 3 The diagram shows a Western blot analysis of the soluble expression product of the peptide and AcNES1 protein according to the present invention. The loading order from left to right is: lane 1: CEN2242; lane 2: CEN2243.
[0223] Figure 4 The diagram shows a Western blot analysis of the peptides according to the present invention and the soluble expression product of SaCas9 in Saccharomyces cerevisiae. The loading order from left to right is: lane 1: CEN2214; lane 2: CEN2213.
[0224] Figure 5The diagram shows a Western blot analysis of the peptides according to the present invention and the soluble expression product of LsLTC2 in Escherichia coli. The loading order from left to right is: Lane 1: protein standard band; Lane 2: BL21(DE3)_pET28a-tERG20-LsLTC2-myc; Lane 3: BL21(DE3)_pET28a-LsLTC2-myc.
[0225] Figure 6 The diagram shows a Western blot analysis of the peptide and the soluble expression product of SaCas9 according to the present invention. The loading order from left to right is: Lane 1: BL21(DE3)_pET28a-tERG20-SaCas9-myc; Lane 2: BL21(DE3)_pET28a-SaCas9-myc.
[0226] Figure 7 The diagram shows the Western blot analysis of the peptide according to the present invention and the soluble expression product of LsLTC2 in Pichia pastoris. The loading order from left to right is: Lane 1: protein standard band; Lane 2: KPC1 sample 1; Lane 3: KPC1 sample 2; Lane 4: KPC1 sample 3; Lane 5: KPC2 sample 1; Lane 6: KPC2 sample 2; Lane 7: KPC2 sample 3.
[0227] Figure 8 A schematic diagram of the biosynthetic pathway of gemmaene A is shown. Detailed Implementation
[0228] The technical solution of the present invention will be further described in detail below with reference to the specification and specific embodiments, but the implementation of the present invention is not limited thereto. Equivalent substitutions, combinations, improvements, or modifications made by those skilled in the art based on the description of the present invention should all be covered within the protection scope of the present invention.
[0229] Unless otherwise stated, the experimental methods used below are conventional methods well known to those skilled in the art, and can be performed using standard procedures described in the following works: Sambrook et al., *Molecular Cloning: A Laboratory Manual* (3rd edition) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA, 2001); Davis et al., *Basic Methods in Molecular Biology* (Elsevier Science Publishing, Inc., New York, USA, 1995); and Juan S. Bonifacino et al., *Current Protocols in Cell Biology* (John Wiley and Sons, Inc.).
[0230] Unless otherwise stated, all reagents and materials used in the following examples are commercially available and can be used without further purification. Experimental materials are listed in Tables 1 to 3.
[0231] Table 1. Carriers and competent cells
[0232]
[0233] Table 2 Information on exogenous and synthetic proteins
[0234]
[0235] Table 3 Plasmid Information
[0236]
[0237] In Saccharomyces cerevisiae CEN.PK-2-1D, Trp1, Leu2, His3, and Ura3 are screening markers for auxotrophic symptom selection. The Leu2 inactivation site in the Saccharomyces cerevisiae genome was repaired to obtain a functional LEU2 expression cassette. The repaired amino acid sequence is shown in SEQ ID NO:74, and the nucleotide sequence is shown in SEQ ID NO:75.
[0238] Myc is a protein tag.
[0239] Main reagents and instruments:
[0240] β-Legumene reference standard: China National Institutes for Food and Drug Control, batch number: 100268-21903, 99.4% purity.
[0241] Nerolidol reference standard: Shanghai Yuanye Biotechnology Co., Ltd., batch number M10HB177727, CAS number: 7212-44-4; specification: analytical standard, HPLC ≥ 98%.
[0242] Gemmaene A reference standard: prepared according to Example 3 of patent CN 108060092 B, 85% purity.
[0243] SD-Leu yeast culture medium: Leu Minus media, Beijing Pan-Gino Technology Co., Ltd.
[0244] Calcium chloride stock solution: 19.2 g / L calcium chloride dihydrate, prepared using purified water.
[0245] Trace metal salt mother liquor: prepared according to the prior art CN108060092B Example 3.
[0246] Vitamin stock solution: 0.2 g / L biotin, 0.8 g / L sodium para-aminobenzoate, 4 g / L niacin, 4 g / L calcium pantothenate, 4 g / L pyridoxine hydrochloride, 4 g / L thiamine hydrochloride, 100 g / L inositol, prepared with purified water.
[0247] Succinic acid stock solution: 60g / L succinic acid, pH adjusted to around 5 with NaOH, and prepared with purified water.
[0248] F2 fermentation medium: 25 g / L glucose, 15 g / L ammonium sulfate, 6.15 g / L magnesium sulfate heptahydrate, 0.72 g / L zinc sulfate heptahydrate, 8 g / L potassium dihydrogen phosphate, 2 mL / L calcium chloride stock solution, 10 mL / L trace metal salt stock solution, 3 mL / L vitamin stock solution, 100 mL / L succinic acid stock solution, prepared with purified water.
[0249] F1 culture medium: 25 g / L glucose, 15 g / L ammonium sulfate, 6.15 g / L magnesium sulfate heptahydrate, 0.72 g / L zinc sulfate heptahydrate, 8 g / L potassium dihydrogen phosphate, 2 mL / L calcium chloride stock solution, 10 mL / L trace metal salt stock solution, 3 mL / L vitamin stock solution, prepared with purified water.
[0250] BMGY medium: 10 g / L yeast extract; 20 g / L peptone; 100 mL / L 1 M potassium phosphate buffer, pH 6.0; 13.4 g / L YNB; 0.4 mg / L biotin; 1% glycerol (v / v).
[0251] YPD medium: 10 g / L yeast extract; 20 g / L peptone; 20 g / L glucose, prepared with purified water.
[0252] LB medium: Solarbio (China).
[0253] n-Dodecane: Analytical grade (AR), Chengdu Kelon.
[0254] Anhydrous ethanol: Analytical grade (AR), Chengdu Kelong.
[0255] CEN.PK-2-1D: Purchased from the European Saccharomyces cerevisiae Archive for Functional Analysis (EUROSCARF, Germany).
[0256] Frozen-EZ Yeast TransformationⅡTM Kit: ZYMO Research (USA).
[0257] Soda lime glass beads: 0.5mm, biospec (USA).
[0258] Real-Band Western Blot two-color prestained protein marker, standard range, 15~180kDa: BBI (China).
[0259] PCR kits: KOD FX kit, Toyobo (Japan); PrimeSTAR® HS DNA Polymerase kit, Takara (Japan); KOD One TM Master Mix Blue reagent kit, Toyobo (Japan).
[0260] Anti-c-Myc Tag antibody: BBI (China), diluted with 1% skim milk powder at a ratio of 1:10000.
[0261] HRP-conjugated Goat Anti-Rabbit IgG: BBI (China), diluted 1:10000 with 1% skim milk powder.
[0262] Ultraviolet spectrophotometer: Thermo Scientific (USA).
[0263] Ultrasonic multi-channel pulverizer: Ningbo Xinzhi (China).
[0264] Electroporation system: Biorad (USA).
[0265] Grinding bead homogenizer: Shanghai Jingxin (China).
[0266] Ultra-micro spectrophotometer: DeNovix (USA).
[0267] 3L fermentation tank: SKC0703-1001C1, Wuhan Saikecheng Technology Co., Ltd. (China).
[0268] Ultra-high performance liquid chromatography: Acquity UPLC-H-Class, Waters (USA).
[0269] Example 1: Strain Construction
[0270] The starting strain was CEN.PK2-1D (MATα; ura3-52, trp1-289, leu2-3,112; his3Δ1; MAL2-8c; SUC2). Unless otherwise specified, the endogenous genes ERG13 (Genebank: CAA65437.1), ERG12 (GenBank: CAA29487.1), ERG8, ERG19 (Genebank: AAC49252.1), IDI1 (Genebank: AAA34708.1), promoter, terminator, and homologous arms of the MVA pathway were all derived from the CEN.PK-2-1D genome.
[0271] Build it as follows:
[0272] (1) Beijing Liuhe Huada was commissioned to synthesize gene expression frames TRP1, ERG12, ERG8 and ERG19, among which, promoter Ptrp1 was selected to start TRP1, promoter Ptef1 was selected to start ERG12, promoter Pfba1 was selected to start ERG8 and Ptef2 was selected to start ERG19; homologous arms XI3-KL and XI3-KR of the XI-3 site were designed, and the homologous arms were derived from the upstream and downstream genomic sequences of the XI-3 site. After obtaining the DNA fragment, overlap extension PCR was used to assemble XI3-KL, Ptrp1-TRP1-Ttrp1, Ptef1, ERG12-Terg12, Pfba1, ERG8-Terg8, Ptef2, ERG19-Terg19, and XI3-KR in sequence to obtain Donor DNA-1: XI-3::Ptrp1-TRP1-Ttrp1-Ptef1-ERG12-Terg12-Pfba1-ERG8-Terg8-Ptef2-ERG19-Terg19, the nucleotide sequence of which is shown in SEQ ID NO:45. Donor DNA-1 was introduced into CEN.PK2-1D strain using the Frozen-EZYeast Transformation II™ Kit to construct strain CEN2037. TRP1 was used as a selection marker to restore its nutritional deficiencies and enhance the expression levels of ERG12, ERG8 and ERG19 genes in the mevalonate pathway.
[0273] (2) Beijing Liuhe Huada was commissioned to synthesize gene expression cassettes such as HIS3, ERG12, ERG13, and EfmvaE. Among them, HIS3 was started by promoter Phis3, ERG12 was started by promoter Ptef1, ERG13 was started by promoter Pgal1, and EfmvaE was started by promoter Pgal10. Homologous arms gal80-KL and gal80-KR were designed to knock out gal80. Donor DNA-2 was assembled using overlap extension PCR in the following order: gal80-KL, Phis3-HIS3-This3, Ptef1, ERG12-Terg12, ERG13-Terg13, Pgal1-10, EfmvaE, gal80-KR, yielding the Δgal80::Phis3-HIS3-This3-Ptef1-ERG12-Terg12-Terg13-ERG13-Pgal1-Pgal10-EfmvaE-Tgal80, with its nucleotide sequence shown in SEQ ID NO:46. Donor DNA-2 was introduced into strain CEN2037 using a yeast transformation kit to construct strain CEN2038. HIS3 was used as a selection marker to restore its nutritional deficiencies, while simultaneously inactivating the GAL80 site and enhancing the expression levels of ERG12, ERG13, and EfMvaE genes in the mevalonate pathway.
[0274] (3) Beijing Liuhe Huada was commissioned to synthesize expression cassettes for genes URA3, ERG20, and IDI1. URA3 was started by promoter Pura3, ERG20 by promoter Ptef1, and IDI1 by promoter Ptef2. The homologous arms LPP1-KL and LPP1-KR were designed to knock out LPP1. After obtaining the fragments, overlap extension PCR was used to assemble LPP1-KL, Pura3-URA3-Tura3, Ptef1, ERG20, Tadh1, Ptef2, IDI1-Tidi1, and LPP1-KR in sequence to obtain Donor DNA-3: Δlpp1::Pura3-URA3-Tura3-Ptef1-ERG20-Tadh1-Ptef2-IDI1-Tidi1, the nucleotide sequence of which is shown in SEQ ID NO:47. Donor DNA-3 was introduced into strain CEN2038 using a yeast transformation kit to construct strain CEN2039. URA3 was used as a selection marker to restore its nutritional deficiencies, and LPP1 was knocked out, while the expression levels of ERG20 and IDI1 genes in the mevalonate pathway were enhanced to increase the flux of farnesyl pyrophosphate (FPP).
[0275] Genotype information for each strain is shown in Table 4.
[0276] Using CEN.PK2-1D (MATα; ura3-52, trp1-289, leu2-3,112; his3Δ1; MAL2-8c; SUC2) as the starting strain, a two-step backfilling of yeast amino acid defect genes was performed via homologous recombination. The first step involved in-situ backfilling of the TRP1 defect gene. The TRP1 gene fragment was obtained from plasmid pESC-TRP (commercially purchased, from Youbao Biotechnology), yielding Donor DNA-4 (nucleotide sequence shown in SEQ ID). NO:48), the yeast transformation kit was used to transfer the genome of strain CEN.PK2-1D, and the TRP1 gene was backfilled in situ to obtain strain CEN64; the second step: the URA3 and HIS3 gene expression cassettes were synthesized by Beijing Liuhe Huada Synthetic Gene, and the DNA fragments Pura3-URA3-Tura3 and Phis3-HIS3-This3 were obtained. The homologous arms of LPP1, LPP1-KL and LPP1-KR, were designed to knock out LPP1. Using overlap extension PCR, LPP1-KL, Pura3-URA3-Tura3, Phis3-HIS3-This3, and LPP1-KR were assembled in sequence to obtain Donor DNA-5: Δlpp1::Pura3-URA3-Tura3-Phis3-HIS3-This3, the nucleotide sequence of which is shown in SEQ ID NO:49. Donor was then transformed into the genome of strain CEN.PK2-1D using a yeast transformation kit. DNA-5 was introduced into CEN64 strain to construct CEN199 strain, which repairs TRP1, URA3, and HIS3 defective genes and knocks out LPP1. Genotypic information of the strain is shown in Table 4.
[0277] Table 4. Strain Information
[0278]
[0279] Example 2 Plasmid Construction
[0280] This experiment truncated wild-type ERG20 to varying degrees to obtain the polypeptide described in this invention. Unless otherwise specified, the linker peptide between the ERG20 polypeptide and LsLTC2 is GGGS. Plasmid information is shown in Table 3. The construction method is as follows:
[0281] Construction of plasmids expressing a fusion protein containing wild-type ERG20 (with a linker peptide): The promoter fragment P was amplified from the CEN.pK2-1D genome using conventional methods. SSA1 (SEQ ID NO:68). The whole genome sequence of ELE-020 (see CN108060092B) was extracted (according to the instructions of the YeaStar Genomic DNA Kit (ZYMO)). The fragment ERG20-GGGS-LsLTC2-T was amplified from the ELE-020 genome. ADH1(SEQ ID NO:69). From plasmid pRS425-LEU2-P MF1- SynSmFPS-GGGS-STpGMAS-T CYC1 (See CN108060092B) The backbone fragment pRS425-Line (SEQ ID NO:70) was amplified. After agarose gel electrophoresis, the fragments were excised and recovered. Ligation was performed using the pEASY®-Basic Seamless Cloning and Assembly Kit (TransGold, China). The ligation system was: pRS425-Line 130ng, P SSA1 70ng, ERG20-GGGS-LsLTC2-T ADH1 115 ng, 6.35 μL of 2×Assembly mix. Conditions: 50℃, 30 min. Transformed into E. coli Trans 5α competent cells (TransGold, China), plated on LB agar plates containing ampicillin, cultured at 37℃ for 16 h, single clones were picked and cultured overnight at 37℃, plasmids were extracted and sequenced to obtain the yeast expression vector pRS425-Pssa1-ERG20-GGGS-LsLTC2-Tadh1 (pLTC2-0).
[0282] The yeast expression vector pL2μ (SEQ ID NO:76) was constructed using homologous recombination, following the instructions of the pEASY®-Basic Seamless Cloning and Assembly Kit (PEASY, China).
[0283] Construction of plasmids expressing fusion proteins containing truncated ERG20 (with linker peptides): ERG20 was truncated and fused with LsLTC2. All truncated peptides retained the start codon methionine. The linker peptide between the truncated ERG20 peptide and LsLTC2 in each fusion protein was identical to that in plasmid pLTC2-0, which was GGGS. The amino acid sequence of the truncated ERG20 peptide is shown in Table 5. The relevant plasmid construction methods are as follows: the vector backbone and target fragment were amplified from plasmid pLTC2-0, and ligation was performed using the pEASY®-Basic Seamless Cloning and Assembly Kit (TransGold, China) according to the instructions. The ligation product was transformed into E. coli chemically competent cells (DH5α, Vazyme) by coli chemical transformation. After sequencing, the corresponding plasmids pLTC2-10, pLTC2-11, pLTC2-15, pLTC2-16, pLTC2-20, pLTC2-21, pLTC2-22, pLTC2-26, pLTC2-27, pLTC2-28, pLTC2-29, pLTC2-41, pLTC2-42, and pLTC2-43 were obtained. The specific information of the plasmids is shown in Table 3.
[0284] Construction of plasmid expressing LsLTC2 alone: DNA fragments without ERG20-GGGS were obtained from plasmid pLTC2-0 using PCR. Following the method for constructing polypeptide plasmids, plasmid pRS425-Pssa1-LsLTC2-Tadh1 (pLTC2-1) was constructed.
[0285] Construction of a plasmid expressing a fusion protein containing a truncated ERG20 (without a linker peptide): The plasmid backbone was obtained from pL2μ and the expression cassette fragment of LsLTC2 was synthesized. At the same time, the coding sequence of the truncated ERG20 peptide (MTLDENYGKKDSVAE) was synthesized and column recovered. Ligation was performed using the pEASY®-Basic Seamless Cloning and Assembly Kit (TransGold, China). The ligation was performed and the cells were transformed into E. coli DH5α competent cells (Vazyme, China). After sequencing, the yeast expression vector pLTC2-68 (SEQ ID NO:77, pL2μ-Pssa1-ERG20(282-295aa)-LsLTC2-Tadh1) was obtained.
[0286] Table 5. Sequences of ERG20 peptides and their truncated forms
[0287]
[0288] Example 3: Production Verification
[0289] 3.1 Strain Construction
[0290] The plasmids expressing ERG20 or its truncated form of the fusion protein constructed in Example 2 were transformed into the CEN2039 strain prepared in Example 1 using a yeast transformation kit to obtain the corresponding strains. The plasmids and strain genotypes are shown in Table 6.
[0291] Table 6 Plasmid and strain information
[0292]
[0293] 3.2 Fermentation and Results
[0294] The constructed strains were subjected to batch fermentation: single clones were selected and cultured overnight at 30°C and 250 rpm to obtain seed culture; 1 mL of seed culture was transferred to a 100 mL shake flask containing 20 mL of F2 medium and cultured at 30°C and 250 rpm for about 40 hours.
[0295] Sample preparation of Gemaene A in shake flasks: Take 750 μL of fermentation broth, add about 500 μL of glass beads and 300 μL of n-dodecane, vortex extract for 30 min, centrifuge at 12000 rpm for 10 min, dilute with anhydrous ethanol to an appropriate multiple and send for testing to determine the content of Gemaene A.
[0296] Liquid chromatography analysis conditions: The chromatographic column was Elispe plus RRHD (1.8 μm, 2.1 × 150 mm), with a sample injection of 1 μL; column temperature 30℃; mobile phase A: water, B: acetonitrile-isopropanol (1:1); flow rate 0.2 mL / min, detection wavelength 210 nm. The gradient program is shown in Table 7.
[0297] Table 7 Gradient Procedure
[0298]
[0299] The results of testing for each transformed strain (engineered bacterium) and its gemathene A yield are shown in Table 8 below:
[0300] Table 8 Production Results
[0301]
[0302] Based on the above test results, further research will be conducted on ERG20 (282-295aa), which will be referred to as tERG20.
[0303] Example 4: Production Verification
[0304] The plasmid used in this experiment was pLTC2-40, constructed according to Example 2, with the fusion protein being ERG20(282-295aa)-LsLTC2. The constructed plasmid was transformed into strain CEN2039 to obtain CEN2140. Plasmid and strain information are shown in Tables 3, 4, and 9. The constructed strain was then subjected to shake-flask fermentation. The fermentation method, gemmaene sample processing method, and detection method are as described in section 3.2.
[0305] The fermentation results are shown in Table 9 below, where the yield of gemmaene A from strain CEN2140 was 970 mg / L.
[0306] Table 9. Strain Information
[0307]
[0308] Example 5: Fermentation Tank Yield Verification
[0309] The plasmid pLTC2-68 (plasmid sequence SEQ ID NO:73) constructed in Example 2 was transformed into strain CEN2039 to obtain strain CEN2172. Strain information is shown in Table 10. After amplification and culture, glycerol was added to the engineered strain CEN2172 to a final concentration of 25% (v / v), mixed thoroughly, dispensed, and frozen at -80℃ to obtain frozen glycerol culture. The constructed engineered strain was fermented in a 3L fermenter. After thawing, the frozen glycerol culture was transferred to F1 medium and cultured overnight at 30℃ and 250 rpm to obtain primary seed culture. The primary seed culture was then transferred to F1 medium at an inoculation ratio of 5-20% (v / v) and cultured at 30℃ and 250 rpm until OD200 was reached. 600 =8-20, to obtain secondary seed culture; transfer the secondary seed culture to the F1 medium of the fermenter at an inoculation ratio of 5-20% (v / v). The fermentation conditions are as follows: (1) Add glucose solution until the cell concentration reaches OD 600 =150-220, then switch to ethanol supplementation, fermentation for 120 hours, and control the ethanol concentration below 5g / L. (2) Parameter settings: temperature 30℃, pH 5.0, dissolved oxygen controlled at 30%.
[0310] Sample processing and analysis after fermentation: Take a 50mL centrifuge tube, add 3mL of purified water, 2mL of dodecane, and finally 2mL of the well-mixed fermentation broth. Place the tube horizontally on a shaker (Changzhou Zhiborui Instrument Manufacturing Co., Ltd., ZD-85) and extract by shaking for 16 hours at 30℃ and 250rpm. Then centrifuge at room temperature and 4200rpm for 10min to obtain the supernatant. Take the supernatant and dilute it with anhydrous ethanol to an appropriate factor. The sample analysis method is the same as in Example 3.2.
[0311] Fermentation results showed that the highest yield of gemmaene A from strain CEN2172 after 120 hours of fermentation was 33 g / L.
[0312] Table 10 Information on strains and genotypes
[0313]
[0314] Example 6: Introduction of ERG9 mutant
[0315] 6.1 Construction of strains and plasmids
[0316] Construction of CEN201 strain: Starting with CEN2039 strain, the Trp selection marker in CEN2039 strain was recovered using the Cre-Loxp system according to the method in the reference, resulting in CEN201 strain, which was then converted into a Trp-deficient type to serve as the selection marker for the next step. (Güldener U, Heck S, Fielder T, Beinhauer J, Hegemann JH. Anew efficient gene disruption cassette for repeated use in budding yeast. Nucleic Acids Res. 1996 Jul 1;24(13):2519-24. doi: 10.1093 / nar / 24.13.2519.PMID: 8692690; PMCID: PMC145975.).
[0317] Construction of CEN2235 and CEN2247 strains: (1) Beijing Liuhe Huada was commissioned to synthesize the expression cassettes of the mutant genes TRP1 and ERG9, and the ERG9 self-promoter Perg9 was selected to start ERG9 (K325E); the homologous arms 1622b-KL and 1622b-KR at the 1622b site were designed; the fragment Ptrp1-TRP1-Ttrp1 was synthesized; 1622b-KL, Perg9-ERG9(R225A / K325E), ERG9(R225A / K325E))-Terg9, and 1622b-KR were obtained from CEN.PK2-1D strain. After obtaining the DNA fragments, overlap extension PCR was used to assemble 1622b-KL, Ptrp1-TRP1-Ttrp1, Perg9-ERG9(R225A / K325E), ERG9(R225A / K325E)-Terg9, and 1622b-KR in sequence to obtain Donor DNA-8 and Donor DNA-9: 1622b-Ptrp1-TRP1-Ttrp1-Perg9-ERG9(R225A / K325E)-Terg9, the nucleotide sequences of which are shown in SEQ ID NO:90-SEQ ID NO:91. Donor DNA-8 and Donor DNA-9 were introduced into strain CEN201 using a yeast transformation kit to construct strains CEN2226 and CEN2239, respectively.
[0318] (2) Plasmid pLTC2-68 (pL2μ-Pssa1-ERG20(282-295aa)-LsLTC2-Tadh1) was introduced into CEN2226 and CEN2239 respectively to obtain strains CEN2230 and CEN2244.
[0319] (3) Design knockout of wild-type ERG9 left and right homologous arms erg9-KL and erg9-KR, obtain Ptef-KanMX-Tadh2 from plasmid pAK-loxp, and obtain erg9-KL and erg9-KR from CEN.PK2-1D strain. After obtaining the DNA fragments, use overlap extension PCR to assemble erg9-KL, Ptef1-KanMX-Tadh1 and erg9-KR in sequence to obtain Donor DNA-10: Δerg9-Ptef-KanMX-Tadh2, whose nucleotide sequence is shown in SEQ ID NO:92. Introduce Donor DNA-10 into CEN2230 and CEN2244 strains using a yeast transformation kit to construct strains CEN2235H and CEN2247.
[0320] Table 11 Information on strains and genotypes
[0321]
[0322] 6.2 Fermentation and Yield
[0323] The constructed strain was subjected to shake-flask fermentation and yield verification: single clones were selected and cultured in SD-Leu liquid medium at 30℃ and 250rpm to obtain seed liquid; 1mL of seed liquid was transferred to 20mL F2 medium (100mL shake flask) and cultured in a shaker at 30℃ and 250rpm until the ethanol was consumed.
[0324] Gemmaene A sample preparation: 500 μL of bacterial culture, 500 μL of glass beads, and 500 μL of dodecane were mixed and placed in a grinder for processing: linear speed: 10 m / s; grinding time: 60 s, interval time: 30 s; grinding times: 5 times; then centrifuged at 12000 rpm for 10 min, and the upper organic phase was taken and diluted with anhydrous ethanol to an appropriate multiple for testing to determine the content of gemmaene A.
[0325] Liquid chromatography analysis conditions: The column was an Elispe plus RRHD (1.8 μm, 2.1 × 150 mm); 1 μL sample was injected; column temperature was 30℃; mobile phase A: water, B: acetonitrile-isopropanol (1:1); flow rate was 0.2 mL / min; detection wavelength was 210 nm. The gradient program is shown in Table 12. Fermentation results are shown in Table 13.
[0326] Table 12 Gradient Procedure
[0327]
[0328] Table 13 Results of shake-flask fermentation
[0329]
[0330] Example 7: Validation of the yield of different proteins
[0331] 7.1 Construction of strains and plasmids
[0332] Primers were designed using pLTC2-68 as a template to obtain plasmid backbones containing or without the truncated ERG20 of this invention. The neroli tert-ol synthase gene AcNES1 (SEQ ID NO: 95) was synthesized by Liuhe Huada. Gene fragments were obtained from plasmids containing AcNES1, and the fragments were ligated using the pEASY®-Basic Seamless Cloning and Assembly Kit (TransGen, China) according to the instructions. The ligation products were transformed into E. coli chemically competent cells via chemical transformation. Sequencing yielded the corresponding plasmids pAcNES1-1 and pAcNES1-2, sequences shown in SEQ ID NO: 97 and SEQ ID NO: 98. The constructed plasmids were introduced into strain CEN2039 using a yeast transformation kit to obtain strains CEN2236 and CEN2238. These strains were then used for shake-flask fermentation to measure neroli tert-ol yield. Plasmid and strain information is shown in Table 14.
[0333] Table 14 Plasmid and strain information
[0334]
[0335] 7.2 Fermentation and Yield
[0336] The fermentation method was the same as in Example 3.2. Nerolidol sample preparation: 500 μL of bacterial culture, 500 μL of glass beads, and 500 μL of dodecane were mixed and placed in a grinder for processing. Linear speed: 10 m / s; grinding time: 60 s, interval time: 30 s; grinding times: 5 times; followed by centrifugation at 12000 rpm for 10 min. The upper organic phase was diluted with anhydrous ethanol to a suitable multiple and sent for analysis. The nerolidol content was detected by HPLC. Detection conditions: column: Elispe plus RRHD (1.8 μm, 2.1 × 150 mm); column temperature: 30℃; mobile phase A: water, mobile phase B: acetonitrile; flow rate: 0.2 mL / min; detection wavelength: 205 nm. HPLC detection showed that the obtained compound and the standard had the same peak time. Fermentation results are shown in Table 15.
[0337] Table 15 Fermentation Results
[0338]
[0339] Example 8: Effect of the truncated polypeptide according to the present invention on increasing the soluble expression of different types of proteins.
[0340] 8.1 Soluble expression of LsLTC2 protein:
[0341] 8.1.1) Plasmid and strain construction: The myc tag was added after the LsLTC2 gene to detect protein expression. The amino acid sequence of myc is EQKLISEEDL and the nucleotide sequence is GAGCAGAAACTCATCTCAGAAGAGGATCTG. Referring to Examples 1 and 2, a series of LsLTC2 plasmids containing the myc tag were constructed using homologous recombination. The specific plasmid information is shown in Table 16.
[0342] The constructed plasmid was transferred into the CEN199 chassis strain constructed in Example 1. The strain and plasmid information are shown in Table 16. The soluble expression of LsLTC2 was detected by Western blotting (WB).
[0343] Table 16 Plasmid and strain information
[0344]
[0345] 8.1.2) Western Blotting (hereinafter referred to as WB)
[0346] (1) Protein expression: Select single clones from the transformation plate and inoculate them into SD-Leu liquid medium. Incubate overnight at 30℃ and 250rpm. Take 1mL of seed culture and transfer it to 20mL F2 medium (100mL shake flask). Incubate at 30℃ and 250rpm for about 24 hours.
[0347] (2) Sample processing: Take 1 mL of bacterial culture, centrifuge at 8000 rpm for 3 min to collect bacterial cells, resuspend the bacterial cells in 750 μL of protein resuspension buffer (PBS buffer + 1 mM EDTA·2Na), add about 500 μL of glass beads for grinding, the program is as follows: run at a linear speed of 15 m / s for 90 s, take out the sample and put it on ice for 1 min; repeat the above steps 5 times.
[0348] (3) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE): Measure the A280 value of the supernatant, adjust it to a uniform value using protein resuspension buffer, and mix the adjusted supernatant with 5× protein loading buffer at a ratio of 4:1; treat at 95℃ for 10 min, centrifuge at 12000 rpm for 1 min; protein sample preparation is complete. Load 10 μL of the prepared protein sample and run at a constant voltage of 120V for an appropriate time.
[0349] (4) Western Blotting: The procedure was performed according to the Bio-RAD Western Blotting standard operating procedure, replacing the BSA in the sealing process with 5% skim milk powder. (https: / / www.bio-rad.com / webroot / web / pdf / lsr / literature / Bulletin_6376.pdf, 2024.10.31) The Western Blotting results of the strain are as follows... Figure 1 The results showed that the truncated peptides of ERG20 (256-304aa), ERG20 (282-295aa), ERG20 (282-289aa), ERG20 (290-295aa), and ERG20 (285-292aa) could significantly increase the soluble expression of LsLTC2.
[0350] 8.2 Soluble Expression of TmCrtE Protein: Primers were designed using pLTC2-52 as a template to obtain plasmid backbones pRS425-myc-line and pRS425-tERG20-myc-line containing or without the truncated polypeptide of this invention. The geraniol geraniol pyrophosphate synthase gene TmCrtE was synthesized by Liuhe Huada. Gene fragments were obtained from the TmCrtE-containing plasmids. The fragments were ligated using the pEASY®-Basic Seamless Cloning and Assembly Kit (TransGen, China) according to the manufacturer's instructions. The ligation products were transformed into chemically competent E. coli cells via coli chemical transformation. Sequencing yielded the corresponding plasmids pTmCrtE-1 (SEQ ID NO:126) and pTmCrtE-2 (SEQ ID NO:127). The constructed plasmids were introduced into CEN199 strain using a yeast transformation kit to obtain strains CEN3210 and CEN3213. Information on plasmids and strains is shown in Tables 3 and 17.
[0351] Table 17 Strain Information
[0352]
[0353] Western blot characterization: The strain culture and sample processing methods were the same as in Example 8.1.2, the difference being the sampling time; Western blot characterization was performed at 24 hours, 28 hours, and 32 hours. The results are shown in […]. Figure 2 This indicates that in the CEN199 strain, the truncated polypeptide of the present invention can significantly increase the soluble expression of TmCrtE.
[0354] 8.3 AcNES1 Protein Investigation: Using pAcNES1-1 and pAcNES1-2 prepared in Example 7.1 as templates, a myc tag was added to the nerolidol synthase gene AcNES1 for protein detection, constructing plasmids pAcNES1-3 and pAcNES1-4, sequences of which are shown in SEQ ID NO:99 and SEQ ID NO:100. These were transformed into CEN199 strain to construct strains CEN2242 and CEN2243. The soluble expression of AcNES1 was detected by Western blotting (see Example 8.1.2). Plasmid and strain information is shown in Table 18.
[0355] Table 18 Plasmid and Strain Information
[0356]
[0357] Western blot characterization: Results are shown in... Figure 3 The truncated peptide of the present invention, when fused with AcNES1, can significantly increase the soluble expression of AcNES1.
[0358] 8.4. Soluble Expression of SaCas9: Using pLTC2-52 prepared in step 8.1 as a template, plasmid backbones pRS425-myc-line and pRS425-tERG20-myc-line with or without the truncated polypeptide of this invention were obtained. Gene fragments were obtained from the SaCas9-containing plasmids. The fragments were ligated using the pEASY®-Basic Seamless Cloning and Assembly Kit (TransGold, China) according to the manufacturer's instructions. The ligation products were transformed into chemically competent E. coli cells via coli chemical transformation. After sequencing, the corresponding plasmids pRS425-Pssa1-tERG20-SaCas9-Myc-Tadh1 and pRS425-Pssa1-SaCas9-Myc-Tadh1 were obtained (sequences shown in SEQ ID NO:101 and SEQ ID NO:102). The constructed plasmids were introduced into CEN199 strain using a yeast chemical transformation kit to obtain strains CEN2214 and CEN2213. Information on plasmids and strains is shown in Table 19.
[0359] Table 19 Plasmid and Strain Information
[0360]
[0361] The WB operation is the same as in Example 8.1.2, and the results are shown below. Figure 4 Western blot results show that the truncated polypeptide of this invention, when fused with SaCas9, can significantly increase the soluble expression of SaCas9.
[0362] Example 9: The effect of the truncated polypeptide of the present invention on increasing protein soluble expression in different species.
[0363] 9.1. The effect of the truncated polypeptide of the present invention on increasing the soluble expression of proteins in prokaryotic Escherichia coli.
[0364] 9.1.1) Measurement based on LsLTC2:
[0365] Plasmid construction: The vector backbone pET28a-line was amplified using PET28a as a template; LsLTC2 fragments containing / not containing the truncated polypeptide of this invention were obtained from pLTC2-52 to obtain LsLTC2-myc and tERG20-LsLTC2-myc; each fragment was ligated using a homologous recombination kit according to the instructions (Full Gold), and the ligation products were transformed into E. coli chemically competent cells by coli chemical transformation. After sequencing, the corresponding plasmids pET28a-LsLTC2-myc (SEQ ID NO:128) and pET28a-tERG20-LsLTC2-myc (SEQ ID NO:129) were obtained.
[0366] Construction of expression strains: The constructed plasmids were chemically transformed into BL21(DE3) via E. coli to obtain expression strains BL21(DE3)_pET28a-tERG20-LsLTC2-myc and BL21(DE3)_pET28a-LsLTC2-myc.
[0367] The strain culture and sample processing were as follows: Seed culture preparation: Single clones were selected from the transformation plate and spread onto LB liquid medium containing kanamycin, and cultured overnight at 37°C and 250 rpm; Transplantation: 1% of the overnight culture was transferred to 50 mL of fresh LB medium containing kanamycin, and cultured at 37°C and 250 rpm until OD600 = 0.6-0.8; 0.5 MIPTG (100 μL) was added to a final concentration of 1 mM, and cultured at 37°C and 250 rpm for another 4 h; The cells were collected by centrifugation and resuspended twice with protein resuspension buffer (PBS buffer + 1 mM EDTA·2Na), and the cells were frozen at -20°C. Sample preparation: Take the bacterial cells frozen at -20℃, add 5 mL of protein resuspension buffer (PBS buffer + 1 mM EDTA·2Na) to each cell, resuspend them, and transfer 2 mL of each to a 15 mL centrifuge tube. Then add 3 mL of PBS (containing 1 mM EDTA) buffer to each tube and sonicate to disrupt the mixture. After disruption, centrifuge at 12000 rpm for 15 min and separate the supernatant and precipitate.
[0368] The subsequent operations for WB are the same as in 8.1.2, and the results can be found in [link to results]. Figure 5Western blot results showed that in Escherichia coli, the truncated polypeptide of this invention, after fusion with LsLTC2, significantly increased the soluble expression of LsLTC2.
[0369] 9.1.2) Determination based on SaCas9:
[0370] Plasmid construction: Primers were designed using PET28a as a template to amplify the vector backbone pET28a-line, obtaining SaCas9-myc and tERG20-SaCas9-myc. The fragments were ligated using a homologous recombination kit according to the instructions (Trugen). The ligation products were transformed into E. coli chemically competent cells by coli chemical transformation. After sequencing, the corresponding plasmids pET28a-SaCas9-myc and pET28a-tERG20-SaCas9-myc were obtained. The sequences are shown in SEQ ID NO:103 and SEQ ID NO:104.
[0371] Construction of expression strains: The constructed plasmids were chemically transformed into BL21(DE3) via E. coli to obtain expression strains BL21(DE3)_pET28a-tERG20-SaCas9-myc and BL21(DE3)_pET28a-SaCas9-myc.
[0372] The bacterial strain culture and sample processing were as follows: Seed culture preparation: Single clones were selected from the transformation plate and spread onto LB liquid medium containing kanamycin, and cultured overnight at 37°C and 250 rpm; Transplantation: The overnight culture was transferred at 1% to 50 mL of fresh LB medium containing kanamycin, and cultured at 37°C and 250 rpm until OD600 = 0.6-0.8; 0.5 M IPTG (100 μL) was added to a final concentration of 1 mM, and cultured at 37°C and 250 rpm for a further period; the bacterial cells were collected by centrifugation and resuspended twice with protein resuspension buffer (PBS buffer + 1 mM EDTA·2Na), and the bacterial cells were frozen at -20°C. Sample processing: The -20°C frozen bacterial cells were resuspended in 5 mL of protein resuspension buffer (PBS buffer + 1 mM EDTA·2Na), and 2 mL of each was transferred to a 15 mL centrifuge tube. Then, 3 mL of PBS (containing 1 mM EDTA) buffer was added to each tube, and the cells were sonicated. After the crushing was completed, the mixture was centrifuged at 12,000 rpm for 15 minutes to separate the supernatant and the precipitate.
[0373] The subsequent operations for WB are the same as in 8.1.2, and the results can be found in [link to results]. Figure 6 Western blot results showed that in E. coli, the truncated polypeptide of this invention, after fusion with SaCas9, significantly increased the soluble expression of SaCas9.
[0374] 9.2. The effect of the truncated polypeptide of the present invention on increasing the soluble expression of proteins in the eukaryotic organism Pichia pastoris.
[0375] Expression strain construction: Pichia pastoris GS115 was selected as the chassis cell. The LsLTC2 gene was inserted into the neutral site PNSIV-10. LsLTC2 expression strains KPC-1 and KPC-2 were constructed through homologous recombination. The genotypes of the strains are shown in Table 3. The construction process is as follows: The promoter GAP was selected to start LsLTC2-myc or tERG20-LsLTC2-myc. Homologous arms PNSIV-10-KL and PNSIV-10-KR at the PNSIV-10 site were designed. The BleoR expression cassette was obtained from pPICZαA. LsLTC2 and tERG20-LsLTC2-myc were amplified from pLTC2-52. PNSIV-10-KL, Pgap, Taox1 and PNSIV-10-KR were amplified from the GS115 genome. After obtaining the relevant fragments, overlap extension PCR was used to assemble PNSIV-10-KL, Pgap, LsLTC2-myc or tERG20-LsLTC2-myc, Taox1, BleoR, and PNSIV-10-KR sequentially to obtain Donor DNA-6 and Donor DNA-7: PNSIV-10::Pgap-LsLTC2-myc-Taox1-BleoR and PNSIV-10::Pgap-tERG20-LsLTC2-myc-Taox1-BleoR, whose nucleotide sequences are shown in SEQ ID NO:66 and SEQ ID NO:67. These fragments were then inserted into the genome of Pichia pastoris strain GS115 via electroporation to obtain strains KPC-1 and KPC-2, as shown in Table 20.
[0376] Table 20 Strain Information
[0377]
[0378] Fermentation and Western blot characterization of KPC-1 and KPC-2: Single clones were selected from the transformation plate and cultured overnight at 30°C and 250 rpm to prepare seed culture; 1 mL of the overnight cultured seed culture was transferred to 20 mL of BMGY medium (containing 1% glycerol) (100 mL shake flask) and cultured at 30°C and 250 rpm for about 40 hours.
[0379] The subsequent operations for WB are the same as in 8.1.2, and the results are shown below. Figure 7 Western blot results showed that, in Pichia pastoris, the truncated polypeptide of this invention, when fused with LsLTC2, significantly increased the soluble expression of LsLTC2.
[0380] Example 10 Preparation of β-elemene
[0381] Gemmaene A fermentation broth obtained in Examples 3 to 6 was taken, and n-dodecane was added at a ratio of 1:2 (V n-dodecane: V fermentation broth), and the mixture was stirred and extracted for 16 h. The organic phase was heated at 150 °C for 2 h to obtain the conversion broth. β-elemene was obtained by silver nitrate silica gel column chromatography and silica gel column chromatography, respectively.
[0382] 1 H NMR (DMSO): δ 5.85-5.78(m, 1H), 4.90-4.86(m, 2H), 4.80-4.78 (m,1H), 4.72(s, 1H), 4.69-4.68 (m, 1H), 4.59 (s, 1H), 2.05-2.01(m, 1H), 1.92(m,1H), 1.72(s, 3H), 1.67(s, 3H), 1.55-1.53(m, 2H), 1.50-1.40 (m, 2H), 1.37-1.33(m, 2H), 0.96(s, 3H)
[0383] 13 C NMR (DMSO): δ 150.46, 150.09, 147.60, 112.67, 110.48, 109.08, 52.23, 45.39, 39.88, 39.84, 32.76, 26.81, 25.08, 21.28, 16.75.
Claims
1. A polypeptide having an amino acid sequence of 6-97 amino acids, the amino acid sequence of the polypeptide corresponding to an amino acid sequence of 6-97 consecutive amino acids selected from amino acid residue 256 to amino acid residue 352 in amino acid sequence SEQ ID NO:
1. Preferably, the amino acid sequence of the polypeptide has 6-29 amino acids, and the amino acid sequence of the polypeptide corresponds to an amino acid sequence consisting of 6-29 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:
1. Preferably, the amino acid sequence of the polypeptide has 11-29 amino acids, and the amino acid sequence of the polypeptide corresponds to an amino acid sequence consisting of 11-29 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:
1. Preferably, the amino acid sequence of the polypeptide has 14-29 amino acids, and the amino acid sequence of the polypeptide corresponds to an amino acid sequence consisting of 14-29 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:
1. Preferably, the amino acid sequence of the polypeptide has 14 amino acids, and the amino acid sequence of the polypeptide corresponds to an amino acid sequence consisting of 14 consecutive amino acids selected from amino acid residues 276 to 304 in amino acid sequence SEQ ID NO:
1.
2. The polypeptide according to claim 1, characterized in that... The polypeptide has an amino acid sequence of 6-97 amino acids. The amino acid sequence of the polypeptide is selected from the following sequences: SEQ ID NO:1, an amino acid sequence consisting of at least 12 consecutive amino acid residues starting from amino acid residue 276; an amino acid sequence consisting of at least 8 consecutive amino acid residues starting from amino acid residue 282; an amino acid sequence consisting of at least 8 consecutive amino acid residues starting from amino acid residue 285; an amino acid sequence consisting of at least 17 consecutive amino acid residues starting from amino acid residue 288; an amino acid sequence consisting of at least 6 consecutive amino acid residues starting from amino acid residue 290; an amino acid sequence consisting of at least 14 consecutive amino acid residues starting from amino acid residue 282; an amino acid sequence consisting of at least 29 consecutive amino acid residues starting from amino acid residue 276; and an amino acid sequence consisting of... The amino acid sequence of the polypeptide is selected from the amino acid sequence SEQ ID NO:1, which consists of at least 49 consecutive amino acid residues starting from amino acid residue 256; the amino acid sequence of the polypeptide is selected from the amino acid sequence SEQ ID NO:1, which consists of at least 20 consecutive amino acid residues starting from amino acid residue 256; the amino acid sequence of the polypeptide is selected from the amino acid sequence SEQ ID NO:1, which consists of at least 25 consecutive amino acid residues starting from amino acid residue 264; the amino acid sequence of the polypeptide is selected from the amino acid sequence SEQ ID NO:1, which consists of at least 97 consecutive amino acid residues starting from amino acid residue 256; preferably, the amino acid sequence of the polypeptide has 6-29 amino acids. The amino acid sequences in NO:1 are: at least 12 consecutive amino acid residues starting from amino acid residue 276, at least 8 consecutive amino acid residues starting from amino acid residue 282, at least 8 consecutive amino acid residues starting from amino acid residue 285, at least 17 consecutive amino acid residues starting from amino acid residue 288, at least 6 consecutive amino acid residues starting from amino acid residue 290, at least 14 consecutive amino acid residues starting from amino acid residue 282, and at least 29 consecutive amino acid residues starting from amino acid residue 276.
3. The polypeptide according to claim 1 or 2, characterized in that... The polypeptide comprises a polypeptide fragment selected from the group consisting of: amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 275 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 352 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 352 of the amino acid sequence shown in SEQ ID NO:1, amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 256 to 275 of the amino acid sequence shown in SEQ ID NO: The amino acid sequence shown in NO:1 consists of amino acids 264 to 288 and a polypeptide fragment having at least 70% sequence identity with it.Preferably, the polypeptide comprises a polypeptide fragment selected from the group consisting of amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO:1, and a polypeptide fragment having at least 70% sequence identity with the above, preferably amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, and amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 288 to 304 of the amino acid sequence shown in SEQ ID NO:1, and amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO:1, amino acids 282 ... The polypeptide comprises amino acids 276 to 304 of the amino acid sequence shown in SEQ ID NO: 1, amino acids 276 to 287 of the amino acid sequence shown in SEQ ID NO: 1, and a polypeptide fragment having at least 70% sequence identity with them. Preferably, the polypeptide comprises a polypeptide fragment selected from the group consisting of amino acids 256 to 304 of the amino acid sequence shown in SEQ ID NO: 1, amino acids 282 to 295 of the amino acid sequence shown in SEQ ID NO: 1, amino acids 282 to 289 of the amino acid sequence shown in SEQ ID NO: 1, amino acids 290 to 295 of the amino acid sequence shown in SEQ ID NO: 1, amino acids 285 to 292 of the amino acid sequence shown in SEQ ID NO: 1, and a polypeptide fragment having at least 70% sequence identity with them. Preferably, the amino acid sequence of the polypeptide is selected from SEQ ID NO: 2-SEQ ID NO: 8, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 62, and SEQ ID NO:
64. The amino acid sequence of the polypeptide, preferably SEQ ID NO:2-SEQ ID NO:8, is selected from SEQ ID NO:58 and SEQ ID NO:2-SEQ ID NO:5, preferably SEQ ID NO:5-SEQ ID NO:
8.
4. The polypeptide according to any one of claims 1-3, characterized in that... The polypeptide is derived from any host source, preferably from yeast, fermenting spores, Candida albicans, Verticillium tumefaciens, more preferably from yeast, and more preferably from Saccharomyces cerevisiae.
5. A method for increasing the soluble expression of a protein, the method comprising co-expressing the polypeptide of any one of claims 1-4 with a target protein.
6. A fusion protein comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises the polypeptide as described in any one of claims 1-4.
7. The fusion protein according to claim 6, characterized in that... The second polypeptide is a core functional protein or gene regulatory protein in biological metabolism and genetic engineering, preferably selected from one or more of gamma-aluminum A synthase (GAS), terpene synthase (TPS), geraniol-geraniol pyrophosphate synthase (GGPPS), and CRISPR-related proteins; preferably, the second polypeptide is gamma-aluminum A synthase, nerolidol synthase, CAS9, or geraniol-geraniol pyrophosphate synthase; preferably, the second polypeptide is gamma-aluminum A synthase or nerolidol synthase; preferably, the second polypeptide is gamma-aluminum A synthase.
8. The fusion protein according to claim 7, characterized in that... The gemmaene A synthase has the amino acid sequence described in SEQ ID NO: 16 or an amino acid sequence having at least 70% identity with it; or the geraniol geraniol pyrophosphate synthase has the amino acid sequence described in SEQ ID NO: 18 or an amino acid sequence having at least 70% identity with it; or the CRISPR-related protein has the amino acid sequence described in SEQ ID NO: 50 or SEQ ID NO: 52 or an amino acid sequence having at least 70% identity with it; or the nerolidol synthase has the amino acid sequence described in SEQ ID NO: 93 or an amino acid sequence having at least 70% identity with it.
9. The fusion protein according to any one of claims 6-8, characterized in that... The nucleic acid encoding the gemmaene A synthase has the nucleic acid sequence described in SEQ ID NO:17; or the nucleic acid encoding the geraniol pyrophosphate synthase has the nucleic acid sequence described in SEQ ID NO:19; or the nucleic acid encoding the CRISPR-related protein has the nucleic acid sequence described in SEQ ID NO:51 or SEQ ID NO:53; or the nucleic acid encoding the nerolidol synthase has the nucleic acid sequence described in SEQ ID NO:
95.
10. The fusion protein according to any one of claims 6-9, characterized in that... The fusion protein has an amino acid sequence as described in any one of SEQ ID NO:20-SEQ ID NO:26, SEQ ID NO:78-SEQ ID NO:81, SEQ ID NO:94, SEQ ID NO:105, and SEQ ID NO:107, or an amino acid sequence having at least 70% identity with such sequences. Preferably, the fusion protein has an amino acid sequence as described in any one of SEQ ID NO:20-SEQ ID NO:26, SEQ ID NO:94, SEQ ID NO:105, and SEQ ID NO:107, or an amino acid sequence having at least 70% identity with such sequences. Preferably, the fusion protein has an amino acid sequence as described in any one of SEQ ID NO:23-SEQ ID NO:26, SEQ ID NO:94, SEQ ID NO:105, and SEQ ID NO:107, or an amino acid sequence having at least 70% identity with such sequences. Preferably, the fusion protein has an amino acid sequence as described in any one of SEQ ID NO:23-SEQ ID NO:26, and SEQ ID NO:94, or an amino acid sequence having at least 70% identity with such sequences. The amino acid sequence described in any one of NO:23-SEQ ID NO:26 or an amino acid sequence having at least 70% identity with it.
11. An isolated nucleic acid, characterized in that... The nucleic acid comprises a nucleotide sequence encoding a polypeptide as described in any one of claims 1-4 or a nucleotide sequence encoding a fusion protein as described in any one of claims 6-10. Preferably, the nucleotide sequence encoding the polypeptide as described in any one of claims 1-4 comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences as described in any one of SEQ ID NO:9-SEQ ID NO:15 or having at least 70% sequence identity with them, preferably nucleotide sequences as described in any one of SEQ ID NO:12-SEQ ID NO:15 or having at least 70% sequence identity with them. Preferably, the nucleic acid encoding the fusion protein as described in any one of claims 6-10 comprises a nucleotide sequence selected from the group consisting of nucleotide sequences as described in any one of SEQ ID NO:27-SEQ ID NO:33, SEQ ID NO:82-SEQ ID NO:85, SEQ ID NO:96, SEQ ID NO:106, SEQ ID NO:108 or having at least 70% sequence identity with them.
12. An expression box, characterized in that... The expression cassette contains a nucleic acid sequence encoding a polypeptide according to any one of claims 1-4, or a fusion protein according to any one of claims 6-10.
13. A carrier, characterized in that... The vector comprises the nucleic acid and / or expression cassette as described in claim 11 or 12.
14. A host cell, characterized in that... The host cell comprises or expresses the fusion protein according to any one of claims 6-10, preferably the host cell is selected from yeast, Escherichia coli, preferably Saccharomyces cerevisiae, Pichia pastoris and Escherichia coli, preferably Saccharomyces cerevisiae, the host cell is unmodified or modified, preferably the modification is an MVA pathway optimization, the MVA pathway optimization is: introducing into the host cell an enzyme encoding a heterologous bifunctional enzyme acetyl-CoA. The host cell contains the gene for C-acetyltransferase / 3-hydroxy-3-methylglutaryl-CoA reductase EfmvaE, overexpression of isopentenyl pyrophosphate isomerase IDI1, overexpression of 3-hydroxy-3-methylglutaryl-CoA synthase ERG13, overexpression of mevalonate kinase ERG12, overexpression of phosphate mevalonate kinase ERG8, overexpression of farnesyl pyrophosphate synthase ERG20, and overexpression of mevalonate pyrophosphate decarboxylase ERG19. Preferably, the host cell contains inactivated or inhibited LPP1 responsible for farnesol synthesis and GAL80 responsible for transcriptional regulation. Preferably, the host cell contains squalene synthase ERG9, the activity or expression level of which is attenuated. This attenuation is achieved by replacing the promoter of the enzyme's encoding gene or by replacing the endogenous squalene synthase with a squalene synthase mutant.
15. Use of the polypeptide, fusion protein, or host cell according to any one of claims 1-10 and 14 in promoting the expression of soluble proteins.
16. Use of the polypeptide, fusion protein, or host cell according to any one of claims 1-10 and 14 in the production of terpenoids, geraniol diphosphate, carotenoids, and CRISPR-related proteins, preferably in the production of terpenoids, geraniol diphosphate, and CRISPR-related proteins, wherein the preferred terpenoids are gemmaene A, elemol, and nerolidol, and the preferred CRISPR-related protein is CAS9.
17. A method for producing terpenoids, the method comprising culturing the host cell of claim 14 and fermenting it.
18. A method for producing gemmaene A and / or nerolidol, characterized in that... This includes culturing the host cell as described in claim 14 and fermenting it.
19. A method for producing β-elemene, characterized in that... include: 1) Fermenting the host cell as described in claim 14 to obtain a fermentation broth; 2) Extract the fermentation broth with an organic solvent and collect the organic phase; 3) The organic phase is heated to obtain β-elemene.
20. The method according to claim 18, characterized in that... The organic solvent is selected from one or more of n-dodecane, isopropyl myristate, n-hexane, and n-heptane, with n-dodecane being preferred.
Citation Information
Patent Citations
A recombinant bacterium and its uses
CN108060092B
